

## PATENT COOPERATION TREATY

PCT

## NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents  
United States Patent and Trademark  
Office  
Box PCT  
Washington, D.C.20231  
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 03 October 2000 (03.10.00)	
International application No. PCT/US00/02943	Applicant's or agent's file reference 6969.32-304
International filing date (day/month/year) 04 February 2000 (04.02.00)	Priority date (day/month/year) 05 February 1999 (05.02.99)
Applicant SCHEULE, Ronald, K. et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:  
30 August 2000 (30.08.00)

☐ in a notice effecting later election filed with the International Bureau on:  
\_\_\_\_\_

2. The election ☒ was  
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer Pascal Piriou Telephone No.: (41-22) 338.83.38
---	---

REC'D 16 MAR 2001

WIPO PCT

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)



Applicant's or agent's file reference 6969.32-304	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US00/02943	International filing date (day/month/year) 04/02/2000	Priority date (day/month/year) 05/02/1999
International Patent Classification (IPC) or national classification and IPC A61K47/48		
Applicant GENZYME CORPORATION et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 8 sheets, including this cover sheet.
  - ☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand  30/08/2000	Date of completion of this report  12.03.2001
Name and mailing address of the international preliminary examining authority:   European Patent Office - Gitschiner Str. 103 D-10958 Berlin Tel. +49 30 25901 - 0 Fax: +49 30 25901 - 840	Authorized officer  Korsner, S-E  Telephone No. +49 30 25901 329  

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/US00/02943

## I. Basis of the report

1. This report has been drawn on the basis of *(substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments (Rules 70.16 and 70.17).)*:

### Description, pages:

1-29 as originally filed

### Claims, No.:

1-20 as originally filed

### Drawings, sheets:

1/7-7/7 as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/US00/02943

☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:

## V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

### 1. Statement

Novelty (N)	Yes:	Claims
	No:	Claims 1-20...but see below
Inventive step (IS)	Yes:	Claims
	No:	Claims 1-20
Industrial applicability (IA)	Yes:	Claims (1-17), 18-19, (20)...see VIII:1 concerning methods for treatment
	No:	Claims

2. Citations and explanations  
**see separate sheet**

## VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:  
**see separate sheet**

## **V. Reasoned statement**

The following documents will be referred to in this opinion:

D1 = WO - A - 9961056 (late-published but refers to earlier relevant art)

D2 = WO - A - 9602555

D3 = US - A - 5 747 471

D4 = Immunobiology; 1997, pages 106-119

D5 = Trends in Microbiology; 1998, pages 23-27

&

D6 = Human Gene Therapy; 20 Jan 1999, pages 223-234; this article was added by the Examiner and has been enclosed to the report

\*\*\*\*\*

### 1. Novelty and inventive step (Article 33 PCT)

#### **I. D6**

The document D6 appears to disclose all the major features of the present Application; see Materials and Methods, Discussion and Figure 5.

It is presumed that the article was indeed made available to the public before the priority date and it will here be considered to take away both novelty and inventive step for the entire scope of the claims.

#### **II. D1-D5**

Having regard to the cited prior art, as well as the background art referred to on pages 1-4, 10 and 23 of the Description, it appears to have been well known in the art [even clinical studies; page 2] to use cationic molecule:DNA-complexes, with i.a. bacterially-derived plasmid DNA.

Whereas Claim 1 includes the definition "without an expressible cDNA insert", there is no such feature in Claim 7.

The purpose of independent Claims 1, 7, and 17 is to generate a protective anti-tumour cell immune response - but this antitumour response seems to be a general immune stimulation (also known in the art); here suggested to be of advantage against tumours too (compare page 3, top, and page 9).

Furthermore, the teaching does not present any specific sequences of such nucleic acid sequences.

Concerning Claims 18-19, which are product claims, the intended use is irrelevant. Certain national regulations may deviate; in a later European phase it is the complex per se that must be novel and inventive.

- - -

As to the inventive step, it is at present supposed that the inventive step is meant (by the Applicant) to be based on the nucleic acid sequence without an expressible cDNA insert, possibly in combination with the intended use.

Note that it is obvious from page 10 of the Description that many known lipids can be used; the inventive cannot therefore be based on the selection of a particularly useful lipid (even GL 67 of Claim 19 is known in the art, see pages 10-11).

The teaching is not very informative about the proper design of the nucleic acid sequences that should be used.

The mere suggestion of the useful property (anti-tumour) seems speculative, and may place an unacceptable burden on the skilled man when carrying out the invention. In case any (per se) anti-tumour nucleic acid sequence [i.e. disregarding those encoding peptides with such activity] is intended, we would face the situation where the Applicant suggests the use of (known) sequences which are delivered by a (known) cationic carrier.

Even though this combination may be novel (which may have to be further examined once the Applicant provides further information) there is no inventive step in selecting one of several known alternative carrier systems.

Note that exemplary immunostimulatory sequences are found in D1 (itself a late-published document), Table 1, where it is said that those sequences were known from earlier applications [those latter are therefore normal prior art and may be introduced later should need be].

See also D2, page 7, in particular line 35, about anti-tumour stimulation.

D4-D5 shed further light on the importance of the CpG rich motifs of Claim 4 - and this feature would be obvious to combine with a carrier that is known to be effective and which has been used in a similar context with (other) nucleic acid sequences.

Concerning the compositions of Claims 18-19 it is noted that the cationic molecule is known from (i.a.) D3, figure 1A; and an anti-tumour use is mentioned in column 23. The combination with the nucleic acid is currently held to be non-inventive (unless it can be shown that the nucleic acid is novel and inventive).

It is not possible to clearly deduct from the Description what inventive activity the Applicant has invested; the teaching appears at first sight to be a mixture of prior art with some speculative broadening - and some examples which more or less seem to confirm the state of the art.

It is supposed that the key feature is the CpG-rich motifs but, as stated above, this is not considered to establish the inventive step.

---

The Applicant has chosen not to submit any amendments or comments during the international phase; the statements in Box V about novelty and inventive step have therefore been given in the negative.

**VIII. Certain observations**

Claims:

1.

Claims 1-17 and 20 refer to methods of treatment, Rule 67.1(iv) PCT and are not acceptable under all national/regional regulations.

In case of a later European phase, the claims may be redrafted according to the Guidelines, C-IV, 4.2.

2.

In Claim 1, the "comprising a complex, said complex" does not add any useful information and could preferably be deleted for the sake of clarity.

See also Claim 7.

3.

In Claim 7, the ", and wherein said administration is for the purpose of stimulating said protective anti-tumour cell immune response" seems to be merely a repetition of the initial lines of said claim.

Note that the proviso of Claim 1 regarding the absence of an expressible cDNA insert is not present in Claim 7.

4.

Claim 12 is unclear in so far as the fragment is not defined.

Description:

5.

The "novel" on page 1, line 1, would be implicit (if granted) and should therefore be deleted.



**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/US00/02943

6.

On page 1 - and repeatedly on the following pages - reference is made to (a) biologically active molecule(s) in connection with the "complex".

However, since the claims refer to nucleic acid sequences with/without an expressible cDNA insert, the Description should be limited to this biological molecule.

[Note that it is not acceptable to enter the search with a limited scope in the claims and then extend the scope by referring to the Description; in case the Applicant wants a broader/different scope he may file a divisional application.]

7.

The "incorporated by reference herein" (etc) on page 1 will not be accepted under all national/regional regulations, e.g. in a later European phase.

8.

On pages 4, 11 and 13 reference is made to plasmids which may or may not contain an expressible cDNA insert.

See VIII:3 (Note) above.

9.

The "preferably" on page 5, line 9, should be deleted and the biologically active molecule is to be defined.

10.

The statements bridging pages 6 and 7 have no clear interpretation.

11.

Depending on the future course, some of the cited documents D1-D6 may have to be identified in the Description as relevant prior art; Rule 5.1(a)(ii) PCT.

The Description should also be restricted to correspond to any later scope that may be submitted by the Applicant.

- - - - -

+31 206685079

D6

XP-000943021

HUMAN GENE THERAPY 10:223-234 (January 20, 1999)  
Mary Ann Liebert, Inc.

## Contribution of Plasmid DNA to Inflammation in the Lung after Administration of Cationic Lipid:pDNA Complexes

NELSON S. YEW, KATHRYN X. WANG, MALGORZATA PRZYBYLSKA, REBECCA G. BAGLEY, MARGARET STEDMAN, JOHN MARSHALL, RONALD K. SCHEULE, and SENG H. CHENG

### ABSTRACT

Cationic lipid-mediated gene transfer to the mouse lung induces a dose-dependent inflammatory response that is characterized by an influx of leukocytes and elevated levels of the cytokines interleukin 6 (IL-6), tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ), and interferon  $\gamma$  (IFN- $\gamma$ ). We have examined the contribution of plasmid DNA (pDNA) to this observed toxicity, specifically the role of unmethylated CpG dinucleotides, which have been previously shown to be immunostimulatory. We report here that complexes of cationic lipid GL-67 and unmethylated pDNA (pCF1-CAT) instilled into the lungs of BALB/c mice induced highly elevated levels of the cytokines TNF- $\alpha$ , IFN- $\gamma$ , IL-6, and IL-12 in the bronchoalveolar lavage fluids (BALF). In contrast, BALF of animals administered either GL-67 alone or GL-67 complexed with SssI-methylated pDNA contained low levels of these cytokines. Similar results were observed using a plasmid (pCF1-null) that does not express a transgene, demonstrating that expression of chloramphenicol acetyltransferase (CAT) was not responsible for the observed inflammation. The response observed was dose dependent, with animals receiving increasingly higher amounts of unmethylated pDNA exhibiting progressively higher levels of the cytokines. Concomitant with this increase in cytokine levels were also elevated numbers of neutrophils in the BALF, suggesting a possible cause-and-effect relationship between neutrophil influx and generation of cytokines. Consistent with this proposal is the observation that reduction of neutrophils in the lung by administration of antibodies against Mac-1 $\alpha$  and LFA-1 also diminished cytokine levels. This reduction in cytokine levels in the BALF was accompanied by an increase in transgene expression. In an attempt to abate the inflammatory response, sequences in the pDNA encoding the motif RRCGY, shown to be most immunostimulatory, were selectively mutagenized. However, instillation of a plasmid in which 14 of the 17 CpG sites were altered into BALB/c mice did not reduce the levels of cytokines in the BALF compared with the unmodified vector. This suggests that other unmethylated motifs, in addition to RRCGY, may also contribute to the inflammatory response. Together, these findings indicate that unmethylated CpG residues in pDNA are a major contributor to the induction of specific proinflammatory cytokines associated with instillation of cationic lipid:pDNA complexes into the lung. Strategies to abate this response are warranted to improve the efficacy of this nonviral gene delivery vector system for the treatment of chronic diseases.

### OVERVIEW SUMMARY

In an attempt to understand the basis for the higher level of toxicity observed in CF patients who received aerosolized complexes of cationic lipid:pDNA, compared with those who received liposomes alone, studies were conducted to examine the role of pDNA in inflammation of the lung. In re-

sponse to reports implicating the possible involvement of CpG motifs in pDNA, we examined the effect of instilling unmethylated and CpG-methylated pDNA into lungs of BALB/c mice. Results of our studies demonstrated that unmethylated, unlike CpG-methylated, pDNA elicited the presence of highly elevated levels of several proinflammatory cytokines in the BALF of treated animals. As reduc-

See point V  
of report

tion of this inflammatory response in the lung led to enhanced transgene expression, attempts were made to abate this response through direct modification of the pDNA vector by site-directed mutagenesis. However, altering several of the CpG motifs RRCGY, shown previously to be most immunostimulatory, did not significantly abate the extent of the observed inflammatory response. These results suggest that a greater understanding of the basis of CpG-mediated inflammation of the lung needs to be attained. It is hoped that with improved understanding of this process, a much less toxic and more efficacious gene delivery vector system could be derived for use in the treatment of chronic lung diseases.

## INTRODUCTION

SIGNIFICANT EFFORTS are ongoing to develop both viral and nonviral gene delivery systems for the treatment of inherited genetic disorders, such as cystic fibrosis (CF). An advantage of using nonviral vectors for gene therapy is the absence of an often robust immune response to viral vector-encoded antigens (Yang *et al.*, 1995; Scheule *et al.*, 1997). Although cationic lipid-mediated gene transfer has been shown in clinical trials to be generally safe, it is not without some overt toxicity. We have previously demonstrated dose-dependent pulmonary inflammation after instillation of a complex of cationic lipid GL-67, neutral colipid DOPE (dioleoylphosphatidylethanolamine), and pDNA into the lungs of BALB/c mice (Scheule *et al.*, 1997). The inflammation was characterized by an influx of leukocytes (predominantly neutrophils) and increased concentrations of the proinflammatory cytokines interleukin 6 (IL-6), tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ), and interferon  $\gamma$  (IFN- $\gamma$ ) in the bronchoalveolar lavage fluid. Histopathological analysis of lung sections from mice treated with the individual components of the complex suggested that the cationic lipid was the major mediator of the observed inflammation (Scheule *et al.*, 1997). However, results of clinical studies in which CF subjects were subjected to either aerosolized liposomes (GL-67:DOPE) alone or cationic lipid:pDNA complexes indicated that bacterially derived pDNA may also be inflammatory (Alton *et al.*, 1998). Each of the cationic lipid:pDNA-treated patients, but not the liposome-treated controls, exhibited mild flu-like symptoms (including fever, myalgia, and a reduction in FEV<sub>1</sub> of approximately 15%) over a period of approximately 24 hr. One possible explanation for this response may be related to the presence of unmethylated CpG dinucleotide sequences in bacterially derived pDNA (Krieg *et al.*, 1995; Klinman *et al.*, 1996; Sato *et al.*, 1996).

Compared with DNA of eukaryotic origin, bacterial genomic DNA contains a 20-fold higher frequency of the dinucleotide sequence CpG. In addition, unlike eukaryotic DNA, in which approximately 80% of the cytosines are methylated, DNAs of prokaryotic origin are relatively unmethylated (Bird, 1993). These differences purportedly allow the vertebrate immune system to recognize and respond to foreign DNA of bacterial origin. In this regard, administration of genomic bacterial DNA into an eukaryotic host has been shown to be capable of eliciting a potent immunostimulatory response, activating B cells, natural killer (NK) cells, and macrophages (Krieg *et al.*, 1995;

Ballas *et al.*, 1996; Sparwasser *et al.*, 1997). Systematic analysis indicated that those sequences harboring the CpG motif 5'-RRCGY-3' were particularly potent at inducing these responses (Krieg *et al.*, 1995). That these effects were a consequence of the methylation status of the CpG dinucleotide sequences was demonstrated by experiments showing that administration of either bacterial genomic DNA or synthetic oligonucleotides bearing the RRCGY sequence that had been premethylated with CpG methylase were significantly less immunostimulatory (Schwartz *et al.*, 1997).

Since plasmid DNAs used in gene transfer studies are invariably isolated from bacterial sources, and because they also necessarily harbor bacterial sequences for propagation in this host, they contain a high frequency of unmethylated CpG sequences. The presence of such motifs in pDNA has been shown to be capable of stimulating a robust helper T cell type 1 response in either transfected monocytes or injected BALB/c mice (Sato *et al.*, 1996; Roman *et al.*, 1997). As such, they may contribute to their effectiveness as DNA vaccines (Lipford *et al.*, 1997; Weiner *et al.*, 1997; Davis *et al.*, 1998; Sparwasser *et al.*, 1998). However, such a response is undesirable for their use in the production of therapeutic gene products. Of particular concern for delivery of genes to the lung was the demonstration that bacterial genomic DNA or oligonucleotides containing immunostimulatory CpG motifs caused inflammation in the lower respiratory tract, increasing both cell numbers and elevated levels of the cytokines TNF- $\alpha$ , IL-6, and macrophage inflammatory protein (MIP-2) (Schwartz *et al.*, 1997).

In this study we examined the contribution of the pDNA component of the cationic lipid:pDNA complex to the inflammation that we have observed on administration of the complex to the lung. The goal was to identify which components of the inflammatory response are elicited specifically by pDNA, and to try to reduce those responses by direct modification of the DNA sequence.

## MATERIALS AND METHODS

### Construction and purification of plasmid DNA

The construction and characterization of the plasmid vector pCF1-CAT encoding the reporter gene product chloramphenicol acetyltransferase (CAT) has been described previously (Yew *et al.*, 1997). pCF1-CAT contains the strong promoter from the human cytomegalovirus (CMV) immediate-early gene, an intron, the bovine growth hormone polyadenylation signal sequence, a pUC origin, and the aminoglycoside 3'-phosphotransferase gene that confers resistance to kanamycin. pCF1-null is analogous to pCF1-CAT except that the cDNA for CAT was deleted. pCFA-299-CAT was constructed by digesting pCFA-CAT (identical to pCF1-CAT except for the addition of a small polylinker 5' of the CMV promoter) with *PmeI* (in the polylinker) and *BglI* (in CMV), blunting the ends with the Klenow fragment of DNA polymerase I, then religating. This results in deletion of nucleotides -522 to -300 (relative to the transcription start site) of the CMV promoter.

Site-directed mutagenesis was performed using the QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA), following the protocol described by the manufac-

## INFLAMMATORY UNMETHYLATED CpG MOTIFS

225

turer. One modification was that multiple sets of oligonucleotides were used simultaneously, allowing mutagenesis of three or more sites in a single reaction. The mutations were confirmed by extensive DNA sequencing and restriction enzyme mapping to check for plasmid integrity. pCFA-299-10M-CAT is deleted of the CpG motifs at nucleotides 88, 118, 141, and 224 (number refers to the C residue within the CpG dinucleotide except where indicated and is based on the pCF1-CAT sequence; see Fig. 5), and contains 10 point mutations at nucleotides 410, 564, 1498 (G to A), 1887, 2419, 2600, 2696, 3473, 4395 (G to A), and 4551.

Plasmid DNA was prepared by bacterial fermentation and purified by ultrafiltration and sequential column chromatography essentially as described previously (Lee *et al.*, 1996; Scheule *et al.*, 1997). The purified preparations contained less than 5 endotoxin units/ $\mu$ g of pDNA as determined by a chromogenic *Limulus* amoebocyte lysate (LAL) assay (BioWhittaker, Walkersville, MD), less than 10  $\mu$ g of protein/mg of pDNA as determined by the micro-BCA assay (Pierce, Rockford, IL), and less than 10  $\mu$ g of bacterial chromosomal DNA/mg of pDNA as determined by a dot-blot assay. They were also essentially free of detectable RNA and exhibited spectrophotometric  $A_{260/280}$  ratios of between 1.8 and 2.0.

*In vitro* methylation of pDNA

Plasmid DNAs were methylated *in vitro* in a 5-ml reaction containing 1 $\times$  NEB buffer 2 (50 mM NaCl, 10 mM Tris-HCl [pH 7.9], 10 mM MgCl<sub>2</sub>, 1 mM dithiothreitol), 160  $\mu$ M S-adenosylmethionine (SAM), 1–3 mg of pDNA, and 1 U of SssI methylase (New England BioLabs, Beverly, MA) per microgram of pDNA. The mixture was incubated at 37°C for 18 hr. Additional SAM was added to a concentration of 160  $\mu$ M after 4 hr of incubation. Mock treatment of pDNA used the same procedure except that the SssI methylase was omitted. Methylated and mock-treated pDNA was centrifuged through a Millipore (Bedford, MA) Probind column, ethanol precipitated, and washed with 70% (v/v) ethanol. The pDNA was resuspended in water to a final concentration of greater than 3 mg/ml. In experiments to examine the effects of SssI-mediated methylation of pDNA, mock-methylated pDNA was always used as a control.

The extent of pDNA methylation was assessed by digesting 0.2–0.5  $\mu$ g of the treated pDNA with 10 U of *Bst*UI or *Hpa*II for 1 hr, then analyzing the pDNA by agarose gel electrophoresis. Methylated pDNA was protected from *Bst*UI and *Hpa*II digestion whereas unmethylated or partially methylated pDNA was cleaved. Gel analysis showed that the methylated pDNA was completely protected from either *Bst*UI or *Hpa*II digestion.

*Nasal instillation of cationic lipid:pDNA complexes into mice*

The cationic lipid:pDNA complexes were formed by mixing equal volumes of GL-67:DOPE (1:2) with pDNA as described previously (Lee *et al.*, 1996) to a final concentration of 0.6:1.2:3.6 mM (GL-67:DOPE:pDNA) or 0.3:0.6:1.8 mM, as indicated in the figure captions. The DNA concentration is expressed in terms of nucleotides, using an average nucleotide

molecular mass of 330 Da. BALB/c mice were instilled intranasally with 100  $\mu$ l of complex as described (Lee *et al.*, 1996; Scheule *et al.*, 1997). The animals were euthanized and their lungs were lavaged 24 hr postinstillation using phosphate-buffered saline (PBS). The recovered bronchoalveolar fluids (BALFs) were centrifuged at 1500 rpm for 4 min, and the resulting supernatants were removed and frozen at –80°C for subsequent cytokine analysis. The cell pellets were resuspended in PBS for microscopic determination of cell number and types.

*Histopathology*

Lungs were fixed by inflation at 30 cm of water pressure with 2% paraformaldehyde and 0.2% glutaraldehyde. Representative samples were taken from each lung lobe, embedded in glycol methacrylate, sectioned, and stained with hematoxylin and eosin. Histopathology on the lung was evaluated in a blinded fashion and graded subjectively using a scale of 0 to 4, where a score of 0 indicates no abnormal findings and a score of 4 reflects severe changes with intense infiltrates (Scheule *et al.*, 1997).

*Inhibition of neutrophil influx*

Neutrophils influx into the lungs of BALB/c mice was inhibited by systemic administration of a combination of antibodies against Mac-1 $\alpha$  and LFA-1 as described previously (Scheule *et al.*, 1997). The monoclonal antibody recognizing murine Mac-1 $\alpha$  (clone M1/70; ATCC TIB 128) was generated from ascites and that recognizing LFA-1 was obtained from R&D Systems (Minneapolis, MN). Briefly, to inhibit neutrophil influx, 100  $\mu$ l of a mixture containing 40  $\mu$ l of Mac-1 $\alpha$  ascites fluid and 40  $\mu$ l of anti-LFA-1 antibody was injected by tail vein into the mice approximately 15 min prior to administration of the cationic lipid:pDNA complex. Mice were sacrificed at various time points postinstillation, their lungs lavaged, and the resulting BALF analyzed for cytokine levels and cell counts.

*Cytokine and CAT activity assays*

Cytokine levels in the mouse BALF were quantitated using enzyme-linked immunosorbent assay (ELISA) kits as specified by the manufacturers. IFN- $\gamma$ , TNF- $\alpha$ , IL-1 $\alpha$ , IL-1 $\beta$ , IL-10, and IL-6 ELISA kits were from Genzyme (Cambridge, MA); murine KC (mKC), MIP-2, and granulocyte-macrophage colony-stimulating factor (GM-CSF) ELISA kits were from R&D Systems, and the leukotriene B<sub>4</sub> ELISA kit was from Perceptive Diagnostics (Cambridge, MA).

Our procedures for processing the lung tissues and assay of CAT enzymatic activity have been described elsewhere (Lee *et al.*, 1996; Yew *et al.*, 1997).

*Statistical analysis*

Data were analyzed by the two-tailed unpaired Student's *t* test, using the StatView software program (SAS Institute, Cary, NC). Data were considered to be statistically significant if *p* was less than 0.05.

## RESULTS


## In vitro methylation of plasmid DNA

The plasmids used in these studies were highly purified and contained predominantly the supercoiled form, less than 1 endotoxin unit/mg of plasmid, and were free of infectious contaminants as determined using a bioburden assay. To assess the role of methylation of CpG dinucleotides in the plasmid DNA on lung inflammation, the purified pDNAs were either methylated or mock methylated *in vitro* using *Escherichia coli* SssI methylase. This enzyme methylates the cytosine residue (C5) within all CpG dinucleotides. The extent of methylation was assessed by monitoring the susceptibility of the modified plasmids to digestion by *Bst*UI or *Hpa*II but not *Msp*I. All SssI-methylated but not the mock-methylated plasmids were completely protected from digestion with *Bst*UI and *Hpa*II (data not shown). Methylation of pCF1-CAT also resulted in an approximately fivefold reduction in expression levels following intranasal administration into lungs of BALB/c mice (see below).

## Cytokine profiles in bronchoalveolar lavage fluid after administration of cationic lipid:pDNA complexes harboring either methylated or unmethylated pDNA

The SssI-methylated (m)pDNA or unmethylated pDNA was complexed with the cationic lipid GL-67:DOPE (herein referred to as GL-67) and then instilled intranasally into BALB/c mice. Separate groups of mice were instilled with either (m)pDNA or unmethylated pDNA alone, or vehicle, and their bronchoalveolar lavage fluids collected for analysis at 24 hr posttreatment.

To determine whether methylation of pDNA affected the inflammatory response in the lungs, we measured the levels of several different cytokines in the BALF 24 hr after instillation. Significantly higher levels of TNF- $\alpha$ , IFN- $\gamma$ , and to a lesser extent IL-6, were found in the BALF of mice that received GL-67:pCF1-CAT when compared with those administered GL-67:(m)pCF1-CAT (Fig. 1). Levels of murine KC were also elevated following instillation of the cationic lipid:pDNA complexes but there was no significant difference in the levels of the cytokines induced by either methylated or unmethylated pDNA complexed with GL-67. In contrast, low levels of these



**FIG. 1.** Cytokine analysis of mouse BALF after instillation of GL-67 complexed with methylated or unmethylated pCF1-CAT. BALB/c mice were instilled intranasally with 100  $\mu$ l of GL-67:(m)pCF1-CAT, GL-67:pCF1-CAT, GL-67 alone, (m)pCF1-CAT, pCF1-CAT, or vehicle (water). BALF was collected 24 hr after instillation and ELISAs were used to measure the levels of various cytokines. (m)pCF1-CAT refers to pCF1-CAT that had been methylated by SssI methylase. Data are expressed as means  $\pm$  SEM.  $n = 3$  animals per group. \* $p < 0.05$ , \*\* $p < 0.01$  compared with GL-67:(m)pCF1-CAT.

## INFLAMMATORY UNMETHYLATED CpG MOTIFS

four cytokines were present after instillation with GL-67 alone, (m)pCF1-CAT alone, or unmethylated pCF1-CAT alone (Fig. 1). Although the levels of TNF- $\alpha$ , IFN- $\gamma$ , and IL-6 were low in the BALF of animals treated with free pDNA compared with complexed pDNA, the levels of these cytokines were invariably higher in the group that received free unmethylated pDNA alone than in the group administered (m)pCF1-CAT. We also assayed for IL-10, leukotriene B<sub>4</sub>, IL-1 $\beta$ , IL-1 $\alpha$ , and GM-CSF but in each case the levels were low and indistinguishable from those attained in naive animals (data not shown). These results indicated that unmethylated pDNA alone was weakly inflammatory in the lung but that this response was exacerbated when the pDNA was present in a complex with GL-67. Furthermore, of the cytokines induced by administration of GL-67:pCF1-CAT complexes to the lung, TNF- $\alpha$ , IFN- $\gamma$ , and a proportion of the IL-6 were primarily due to the presence of unmethylated pDNA. The cationic lipid GL-67 did not contribute significantly to the cytokine induction in the BALF with the exception of mKC, where it appeared to work in concert with pDNA to increase its level.

The character of the inflammatory response induced by GL-67:pCF1-CAT was also evaluated by measuring the total number of cells and the differential cell counts recovered in the BALF of the treated animals. Elevated numbers of cells were present in the BALF of mice that were instilled with GL-67:pDNA compared with mice that received either GL-67 alone or pDNA alone (Fig. 2A). The methylation status of the pDNA in the GL-67:pDNA complex did not significantly affect the overall cell number. However, animals administered (m)pCF1-CAT alone (three separate experiments) consistently showed a slight but not statistically significant reduction in the total number of cells in comparison with those that received pCF1-CAT. An analysis of the different cell types showed an increased proportion of neutrophils in mice that received GL-67:pCF1-CAT compared with mice that received GL-67:(m)pCF1-CAT (Fig. 2B). This increase was also observed after instillation of pCF1-CAT alone compared with (m)pCF1-CAT. Together, these data indicate that the induction of cellular influx was mediated by both the cationic lipid and pDNA. However, administration of unmethylated pDNA rather than methylated pDNA into the lung can result in an increase in the proportion of neutrophils in the BALF.

Since pCF1-CAT expresses high levels of the CAT reporter enzyme, which is a bacterial protein, there was the possibility that the cytokine response was due to the expression of the foreign protein. Therefore these experiments were repeated using a plasmid vector that contained the same plasmid backbone but lacked any transgene (pCF1-null). The cytokine induction profile after administration of methylated or unmethylated pCF1-null complexed with GL-67 was essentially identical to that attained with pCF1-CAT (data not shown). This confirmed that the plasmid DNA itself and not expression of the bacterial CAT was responsible for the observed cytokine induction.

## Dose-dependent relationship between unmethylated pDNA and cytokine levels

To determine whether there was a dose-dependent relationship between the amount of unmethylated pDNA administered to the lung and the levels of induced cytokines, (m)pCF1-CAT




FIG. 2. Total cell counts (A) and proportion of neutrophils (B) in BALF after administration of cationic lipid:pDNA complexes. BALB/c mice were instilled intranasally with 100  $\mu$ l of GL-67:(m)pCF1-CAT, GL-67:pCF1-CAT, GL-67 alone, (m)pCF1-CAT, pCF1-CAT, or vehicle. BALF was collected 24 hr postinstillation and total cells and the different cell types were counted. (m)pCF1-CAT refers to pCF1-CAT that had been methylated by *Sss*I methylase. Data are expressed as means  $\pm$  SEM.  $n = 3$  animals per group. \* $p < 0.05$  compared with GL-67:(m)pCF1-CAT or (m)pCF1-CAT.

was mixed with pCF1-CAT at different ratios before complexing with GL-67. The dose of GL-67 and the total amount of nucleotides delivered remained constant. In this experiment MIP-2 and IL-12 were assayed in addition to TNF- $\alpha$ , IFN- $\gamma$ , IL-6, and mKC. As the proportion of unmethylated pCF1-CAT in the complex increased, there was a corresponding increase in the levels of TNF- $\alpha$ , IFN- $\gamma$ , IL-6, and IL-12 (Fig. 3). With IFN- $\gamma$ , IL-6, and IL-12, the stimulated increase in cytokine levels plateaued when the ratio of methylated:unmethylated pDNA was 1:2. This dose-dependent relationship supports the proposal that the induction of TNF- $\alpha$ , IFN- $\gamma$ , IL-6, and IL-12 in the BALF was in direct response to the presence of unmethylated


+31 206685079

pDNA. This trend was not observed for either mKC or MIP-2 (Fig. 3), consistent with the observations above (Fig. 1).

#### Histopathological changes in the lung after administration of cationic lipid:methylated pDNA complexes

The histopathological changes within BALB/c mouse lungs following administration of either cationic lipid alone, pDNA alone, or cationic lipid:pDNA complexes were also examined. BALB/c mice were instilled intranasally with GL-67:(m)pCF1-CAT, GL-67:pCF1-CAT, GL-67 alone, (m)pCF1-CAT, pCF1-CAT, or water (vehicle control). Mice were sacrificed 2 days postinstillation and the lungs were processed for histological examination in a blinded manner. Consistent with our previous

findings (Scheule *et al.*, 1997), multifocal areas of alveolar inflammation were observed in mice that received GL-67:pDNA complexes. The extent of lung inflammation was graded using a scale from 0 to 4, with 0 indicating no abnormalities, 1 indicating a minimal change, 2 a mild change, 3 a moderate change, and 4 representing severe changes from a normal lung (Fig. 4). There was no significant difference in the inflammation score of lungs that received GL-67:pDNA compared with lungs that received GL-67:(m)pDNA complex. Lungs that received GL-67 alone were scored slightly lower than lungs that received lipid:pDNA complex, while minimal inflammation was observed in lungs that received either pDNA or (m)pDNA alone. These results indicate that the presence of unmethylated CpG motifs in the pDNA did not significantly affect the histopathological changes observed in the lung after administration of



**FIG. 3.** Cytokine analysis of mouse BALF after instillation of GL-67 complexed with mixtures of methylated and unmethylated pCF1-CAT. SssI-methylated pCF1-CAT was mixed with unmethylated pCF1-CAT at ratios of 0:3, 1:2, 2:1, or 3:0 [(m)pCF1-CAT:pCF1-CAT], then complexed with GL-67 to final concentration of 0.3:1.8 mM (GL-67:pDNA). BALB/c mice were instilled intranasally with 100  $\mu$ l of GL-67:pDNA complexes and BALF was collected 24 hr after instillation for cytokine assays. Naïve animals were treated with vehicle. (m), Methylated pCF1-CAT; (un), nonmethylated pCF1-CAT. Data are expressed as means  $\pm$  SEM.  $n = 3$  animals per group.

## INFLAMMATORY UNMETHYLATED CpG MOTIFS

229




FIG. 4. Histopathological analysis of BALB/c mouse lung sections following administration of GL-67 complexed with methylated or unmethylated pCFI-CAT. BALB/c mice were instilled intranasally with 100  $\mu$ l of GL-67:(m)pCFI-CAT, GL-67:pCFI-CAT, GL-67 alone, (m)pCFI-CAT, pCFI-CAT, or vehicle. Groups of three mice were sacrificed 2 days postinstillation and the lungs were processed for histological examination in a blinded manner. Lung inflammation was graded on a scale of 0 to 4, with 0 indicating no change, 1 a minimal change, 2 a mild change, 3 a moderate change, and 4 indicating a severe change from a normal lung. (m)pCFI-CAT refers to pCFI-CAT that had been methylated by *SssI* methylase. Data are expressed as means  $\pm$  SEM.

cationic lipid:pDNA complexes. Furthermore, as reported previously, the majority of the histological changes observed on administration of the complexes was mediated by the cationic lipid component (Scheule *et al.*, 1997).

#### Effect of mutating immunostimulatory CpG motifs within pCFI-CAT

If a subset of the unmethylated CpG dinucleotides present in pCFI-CAT was responsible for the majority of the cytokine responses, then elimination of these particular CpG motifs may reduce the level of induction. There are 17 motifs in pCFI-CAT having the sequence 5'-RRCGYY-3', which have been previously shown by Krieg *et al.* (1995) to be the sequence context in which the CpG motif was found to be most immunostimulatory (Fig. 5). Fourteen of these motifs were eliminated by either deletion or site-directed mutagenesis. The four CpG motifs located within the CMV promoter (at nucleotide positions 88, 118, 141, and 224) were removed by deletion of a 400-bp fragment containing a portion of the upstream enhancer region, to create pCFA-299-CAT (Fig. 5). Ten of the 13 remaining motifs (at positions 410, 564, 1497, 1887, 2419, 2600, 2696, 3473, 4394, and 4551) were modified using site-directed mutagenesis to create pCFA-299-10M-CAT (Fig. 5). The cytosine residue

in each motif was mutated to a thymidine, with the exception of nucleotide 1497 within the coding sequence for CAT, and nucleotide 4394 within the kanamycin resistance gene. With these two motifs, in order to preserve the coding sequence for the respective proteins, the guanidine residue of the CpG dinucleotide was changed to an adenosine residue. We were unable to mutate the residue at nucleotide 2789, which is located within the proximity of the origin and that we speculate may be essential for plasmid replication.

The plasmids pCFI-CAT, (m)pCFI-CAT, pCFA-299-CAT, and pCFA-299-10M-CAT were complexed with cationic lipid GL-67 and then instilled intranasally into BALB/c mice. Twenty-four hours after instillation, BALF was collected for cytokine analysis and the lungs harvested for CAT assays. Expression from pCFA-299-CAT, containing the truncated CMV promoter, was approximately one-third that of pCFI-CAT (Fig. 6). The expression from pCFA-299-10M-CAT was equivalent to that from pCFA-299-CAT, indicating that the introduction of the 10 point mutations did not affect transgene expression (Fig. 6). As before, high levels of TNF- $\alpha$ , IFN- $\gamma$ , IL-6, and IL-12 were present in the BALF of mice that received unmethylated pCFI-CAT (Fig. 7). However, equally high levels of these cytokines were also observed with pCFA-299-CAT and pCFA-299-10M-CAT. Therefore, reducing the content of CpG motifs within the plasmid did not reduce its ability to elevate cytokine levels in the lung. This suggests that removal of other immunostimulatory motifs in addition to those harboring the consensus 5'-RRCGYY-3' may be necessary to abate the inflammatory response.

#### Effect of inhibiting neutrophil influx and cytokine activation in the lung on CAT expression

Although mutation of the plasmid vector was ineffective at reducing the inflammation in the lung, we have previously shown that injection of antibodies against Mac-1 $\alpha$  and LFA-1 can limit the influx of neutrophils and induction of TNF- $\alpha$  (Scheule *et al.*, 1997). This method was used to determine the effect of reducing the inflammatory response on CAT expression. Mice were injected via the tail vein with a mixture of the two antibodies just prior to instillation of GL-67:pCFI-CAT into the lung. Cell types and cytokines in the BALF were assayed 24 hr postinstillation and CAT activity in the lung was assayed on days 2 and 7 postinstillation. In mice that were pretreated with the antibodies, there was a significant decrease in the number of neutrophils in the BALF as well as decreased levels of TNF- $\alpha$ , IFN- $\gamma$ , and IL-12 (Fig. 8). Concomitant with this decrease in cytokine levels was a greater than fourfold increase in CAT expression on day 2 postinstillation (Fig. 9). Approximately equivalent levels of CAT were present on day 7. These findings suggest that by reducing the neutrophil influx and cytokine induction in the lung a significant enhancement in transgene expression could be attained.

## DISCUSSION

#### Presence of unmethylated CpG dinucleotides in plasmid DNA is inflammatory in the lung

In this study we have shown that plasmid DNA contributes significantly to the cytokine response observed following ad-






FIG. 5. RRCGYG CpG motifs present in pCF1-CAT. The motifs having the sequence 5'-RRCGYG-3' are shown. Numbers in parentheses indicate the nucleotide position of the cytosine residue, Kan R, kanamycin resistance gene; CMV, cytomegalovirus promoter; CAT, cDNA for chloramphenicol acetyltransferase; BGH Poly A, polyadenylation sequence from bovine growth hormone gene.

ministration of cationic lipid:pDNA complexes to the lung. Most of the increase in the levels of TNF- $\alpha$ , IFN- $\gamma$ , IL-12, and IL-6 and a proportion of the cellular influx observed in the BALF following delivery of cationic lipid:pDNA complexes was shown to be attributable to the pDNA. The basis for this inflammatory response was determined to be due to the presence of unmethylated CpG dinucleotides in the pDNA. The involvement of the CpG dinucleotides was implicated from experiments demonstrating that the inflammatory response could be abated by methylating the pDNA with a CpG methylase. Furthermore, a dose-response relationship was attained between the amount of unmethylated pDNA used in the instillation and the levels of cytokines induced. These results are congruent with previous reports using bacterial genomic DNA and synthetic oligonucleotides, indicating that unmethylated CpG motifs are capable of eliciting an acute inflammatory response in the airways (Schwartz *et al.*, 1997). Activation of a similar cytokine profile by CpG dinucleotides has also been reported in lymphocytes (Klinman *et al.*, 1996), murine dendritic cells (Sparwasser *et al.*, 1998), macrophages (Lipford *et al.*, 1997), monocytes (Sato *et al.*, 1996), and NK cells (Cowdery *et al.*, 1996).

One study also reported that complexes formed between the cationic lipid DOTMA (*N*-[1-(2,3-dioleoyloxy)propyl]-*N,N,N*-trimethylammonium chloride) and pDNA enhanced cytokine and cellular levels in the BALF of treated animals (Freimark *et al.*, 1998). Our results concur in several respects, but there are some differences. Unlike Freimark *et al.* (1998), who noted that only IL-12 was induced by unmethylated pDNA, we observed that TNF- $\alpha$ , IFN- $\gamma$ , IL-12, and to a lesser extent IL-6 were all affected. In addition, ad-

ministration of the cationic lipid DOTMA by itself induced elevated levels of TNF- $\alpha$  whereas administration of GL-67 alone did not. This discrepancy may be due to the differing nature of the interaction of the cationic lipid with the cell. DOTMA differs from GL-67 in chemical structure and charge density, and in its toxicity profile.

#### Both cationic lipid and plasmid DNA contribute to inflammation in the lung

Induction of the inflammatory response by unmethylated pDNA was significantly exacerbated on complexing with a cationic lipid. This enhanced response was likely due to increased cellular uptake of the pDNA by the cells. Consistent with this proposal is the observation that CpG oligonucleotides covalently linked to a solid support such that they are no longer internalized, are nonstimulatory (Krieg *et al.*, 1995; Krieg, 1995). Interestingly, although cytokine levels were greatly elevated on administration of GL-67:pDNA compared with GL-67:(m)pDNA, the histopathological changes associated with either complex were not significantly dissimilar. This suggests that the toxicity mediated by the cationic lipid component and that by the pDNA may be partly distinct. The cationic lipid, by virtue of its amphipathic nature, was probably responsible for




FIG. 6. Relative levels of CAT expression following methylation or mutagenesis of pCF1-CAT. BALB/c mice were instilled intranasally with 100  $\mu$ l of GL-67:pCF1-CAT, GL-67:(m)pCF1-CAT, GL-67:pCFA-299-CAT, or GL-67:pCFA-299-10M-CAT. pCFA-299-CAT harbors a partial deletion of the CMV promoter and pCFA-299-10M-CAT, an additional 10 mutations at CpG sites harboring the sequence motif RRCGYG. (m)pCF1-CAT refers to pCF1-CAT that had been methylated by *Sss*I methylase. Lungs were harvested for CAT analysis on day 2 postinstillation. Data are expressed as means  $\pm$  SEM.  $n = 3$  animals per group.

## INFLAMMATORY UNMETHYLATED CpG MOTIFS

231




FIG. 7. Cytokine analysis of mouse BALF after instillation of GL-67 complexed with pCF1-CAT and modified forms of pCF1-CAT containing reduced numbers of CpG motifs. BALB/c mice were instilled intranasally with 100  $\mu$ l of GL-67:pCF1-CAT, GL-67:(m)pCF1-CAT, GL-67:pCFA-299-CAT, or GL-67:pCFA-299-10M-CAT. BALF was collected 24 hr after instillation and ELISAs for TNF- $\alpha$ , IFN- $\gamma$ , IL-6, and IL-12 were performed. (m)pCF1-CAT refers to pCF1-CAT that had been methylated by *Sss*I methylase. pCFA-299-CAT harbors a partial deletion of the CMV promoter and pCFA-299-10M-CAT, an additional 10 mutations at CpG sites harboring the sequence motif RRCGY. Data are expressed as means  $\pm$  SEM.  $n = 3$  animals per group.

the majority of the physical damage to the cellular membranes, presumably through a detergent-like activity. Pooling of the complexes in the parenchyma following the bolus instillation into the lung also likely potentiated this effect (Eastman *et al.*, 1997). In contrast, the induction of cytokines and the increase in a proportion of the cellular infiltrates, particularly of neutrophils in the BALF, were most likely the effect of the pDNA component. The concomitant presence of neutrophils and cytokines in the BALF suggests that the leukocytes may be a source of the cytokines. That a reduction in neutrophil concentration in the BALF by administration of antibodies to Mac-1 $\alpha$  and LFA-1 was coincident with a decline in cytokine levels is consistent with this proposal. Finally, some of the observed inflammatory responses were likely a consequence of the complexed cationic lipid:pDNA. Examples of these include activation of the cytokine mKC and recruitment of other cells into the BALF, such as macrophages and lymphocytes (Scheule *et al.*, 1997), presumably to clear the relatively large particulates of complexed cationic lipid:pDNA.


#### Implications for use of cationic lipid:pDNA complexes in gene therapy

The observation in a clinical study of CF subjects (Alton *et al.*, 1998), wherein those who received aerosolized GL-67:pDNA presented more frequent and severe adverse symptoms than did those that received aerosolized GL-67 alone, is consistent with pDNA having an inflammatory activity in the lung. Although the inflammatory sequelae of aerosolized GL-67:pDNA in the CF subjects was mild and transient, it is clearly undesirable and possibly limiting for the long-term treatment of chronic diseases such as CF. Current plasmid expression vectors are only capable of facilitating transient expression in the lung, making frequent repeat administrations of the cationic lipid:pDNA complexes necessary (Lee *et al.*, 1996; Yew *et al.*, 1997). Strategies to reduce this inflammatory response and approaches to effect longer term persistence of expression from pDNA vectors are clearly necessary for this gene delivery vector system to be viable and efficacious in the treatment of chronic diseases.

+31 206685079

232

YEW ET AL.




**FIG. 8.** Effect of inhibiting neutrophil influx on cytokine levels in the BALF of BALB/c mice. Animals were injected via the tail vein with a mixture of antibodies against murine LFA-1 and Mac-1 $\alpha$  approximately 15 min prior to instillation of GL-67:pCF1-CAT into the lung. Mice were sacrificed 24 hr postinstillation and BALF was collected for cell counts and cytokine quantitation. Control mice received no antibody prior to instillation of complex, or were instilled with water (Vehicle). Ab refers to group that had been treated with the antibodies. Data are expressed as means  $\pm$  SEM.  $n = 3$  animals per group. \* $p < 0.05$  compared with Ab + complex.

The generation of elevated levels of cytokines in the BALF also has consequences for expression of the therapeutic protein. Several viral promoters (such as the CMV promoter) commonly used in gene delivery vectors are subject to suppression by inflammatory cytokines (Gribaudo *et al.*, 1993; Harms and Splitter, 1995; Qin *et al.*, 1997). Furthermore, any additional inflammation or reduction in lung function in patients that already exhibit chronically inflamed, compromised airways represents an increased safety risk. For CF and other inherited genetic disorders, another consequence of the presence of immunostimulatory CpG motifs maybe the increased likelihood of developing neutralizing antibodies to the therapeutic transgene (Sato *et al.*, 1996; Davis *et al.*, 1998). This is particularly pertinent in subjects harboring either null mutations or mutations that result in the generation of a severely altered variant. Eliminating the adjuvant effect of the immunostimulatory CpG motifs would again be desirable to reduce this risk.

#### Approaches to reduce the inflammatory response to unmethylated plasmid DNA

Given the preceding considerations, strategies to minimize the immunostimulatory effects of CpG dinucleotides in pDNA are clearly warranted. While methylation of the CpG motifs suppressed the inflammation in the lung, this approach is im-



**FIG. 9.** Effect of inhibiting neutrophil influx on CAT expression in the lung. BALB/c mice were injected via the tail vein with a mixture of antibodies against murine LFA-1 and Mac-1 $\alpha$  approximately 15 min prior to instillation of GL-67:pCF1-CAT into the lung. Hatched bars, GL-67:pCF1-CAT; solid bars, GL-67:pCF1-CAT plus antibodies. Mice were sacrificed 2 and 7 days postinstillation and the lungs assayed for CAT activity. Data are expressed as means  $\pm$  SEM.  $n = 4$  or 5 animals per group.

## INFLAMMATORY UNMETHYLATED CpG MOTIFS

233

practical since it also severely reduced expression of the transgene. Indeed, it has been known that methylation of CpG is associated with long-term inactivation of certain genes during mammalian development (Boyles and Bird, 1991; Li *et al.*, 1993) and in the repression of viral genomes (Groudine *et al.*, 1981). In this regard, selection of promoters that lack CpG motifs or are insensitive to methylation may represent an approach that bypasses this impediment. However, the only known such promoter, the Mo-MuLV LTR (Moloney murine tumor virus long terminal repeat) is a weak promoter (Muiznieks and Dorerfler, 1994).

Another approach is to genetically alter those CpG motifs that have been shown to exhibit potent immunostimulatory activity. However, our attempts to reduce the number of occurrences of the most immunostimulatory motif 5'-RRCCGY-3' in pCF1-CAT did not alter the inflammatory profile in the mouse lung. This is not entirely unexpected and suggests that other CpG dinucleotides that are not within the sequence context of RRCCGY also contribute to cytokine induction. Identification of these additional motifs and their removal by site-directed mutagenesis would be necessary for this approach to be effective. It should be noted that the complete removal of all CpG dinucleotides involved in this process is unlikely since some will invariably be located within the nonwobble positions of coding sequences and in bacterial origins of replication. In fact, we speculate that part of our inability to isolate a mutant harboring an alteration at nucleotide position 2789 in pCF1-CAT may be related to the proximity of this nucleotide to the origin.

Yet another approach derives from the interesting observations by Krieg *et al.* (1998) of the presence of CpG motifs that exhibit neutralizing activity. These neutralizing motifs are purportedly capable of countering those with immunostimulatory activity. As such, the incorporation of these neutralizing motifs coupled with the removal of those exhibiting immunostimulatory activity from pDNA vectors may reduce the inflammatory response in the lung. Finally, to evaluate all these strategies, it is also important to consider the animal model. The inflammatory response in mice is likely to be different from that in humans and it is not clear whether there are differences in the ability and sensitivity of mice and humans to respond to particular unmethylated CpG motifs.

## ACKNOWLEDGMENTS

We gratefully acknowledge Maricela Alcantara, Dana Levasseur, and Nick Wan for plasmid DNA production and purification; Mathieu Lanc and David Harris for GL-67 formulations; Amy Gates for assistance with the cell counts and differentials; David Garlick for histopathological analysis; and Johanne Kaplan for critical reading of the manuscript.

## REFERENCES

- ALTON, E.W.F.W., GEDDES, D.M., GILL, D.R., HIGGINS, C.F., HYDE, S.C., INNES, J.A., and PORTEOUS, D.J. (1998). Towards gene therapy for cystic fibrosis: A clinical progress report. *Gene Ther.* 5, 291-292.
- BALLAS, Z.K., RASMUSSEN, W.L., and KRIEG, A.M. (1996). Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. *J. Immunol.* 157, 1840-1845.
- BIRD, A.P. (1993). Functions for DNA methylation in vertebrates. *Cold Spring Harb. Symp. Quant. Biol.* 58, 281-285.
- BOYLES, J., and BIRD, A. (1991). DNA methylation inhibits transcription indirectly via a methyl-CpG binding protein. *Cell* 64, 1123-1134.
- COWDERY, J.S., CHACE, J.H., YI, A.K., and KRIEG, A.M. (1996). Bacterial DNA induces NK cells to produce IFN- $\gamma$  in vivo and increases the toxicity of liposaccharides. *J. Immunol.* 156, 4570-4575.
- DAVIS, H.L., WEERANTA, R., WALDSCHMIDT, T.J., TYGRET, L., SCHORR, J., and KRIEG, A.M. (1998). CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. *J. Immunol.* 160, 870-876.
- EASTMAN, S.J., LUKASON, M.J., TOUSIGNANT, J.D., MURRAY, H., LANE, M.D., ST. GEORGE, J.A., AKITA, G.Y., CHERRY, M., CHENG, S.H., and SCHEULE, R.K. (1997). A concentrated and stable aerosol formulation of cationic lipid:DNA complexes giving high-level gene expression in mouse lung. *Hum. Gene Ther.* 8, 765-773.
- FREIMARK, B.D., BLEZINGER, H.P., FLORACK, V.J., NORDSTROM, J.L., LONG, S.D., DESHPANDE, D.S., NOCHUMSON, S., and PETRAK, K.L. (1998). Cationic lipids enhance cytokine and cell influx levels in the lung following administration of plasmid: Cationic lipid complexes. *J. Immunol.* 160, 4580-4586.
- GRIBAUDO, G., RAVAGHIA, S., CALIENDO, A., CAVALLO, R., GARIGLIO, M., MARTINOTTI, M.G., and LANDOLFO, S. (1993). Interferons inhibit onset of murine cytomegalovirus immediate-early gene transcription. *Virology* 197, 303-311.
- GROUDINE, M., EISENMAN, R., and WEINTRAUB, H. (1981). Chromatin structure of endogenous retroviral vector genes and activation by an inhibitor of DNA methylation. *Nature (London)* 292, 311-317.
- HARMS, J.S., and SPLITTER, G.A. (1995). Interferon-gamma inhibits transgene expression driven by SV40 or CMV promoters but augments expression driven by the mammalian MHC I promoter. *Hum. Gene Ther.* 6, 1291-1297.
- KLINMAN, D.M., YI, A.K., BEAUCAGE, S.L., CONOVER, J., and KRIEG, A.M. (1996). CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin-6, interleukin-12, and interferon-gamma. *Proc. Natl. Acad. Sci. U.S.A.* 93, 2879-2883.
- KRIEG, A.M. (1995). Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA. *Trends Microbiol.* 4, 73-76.
- KRIEG, A.M., YI, A.K., MATSON, S., WALDSCHMIDT, T.J., BISHOP, G.A., TEASDALE, R., KORETZKY, G.A., and KLINMAN, D.M. (1995). CpG motifs in bacterial DNA trigger direct B-cell activation. *Nature (London)* 374, 546-549.
- KRIEG, A.M., WU, T., WEERATNA, R., EFFLER, S.M., LOVEHOMAN, L., YANG, L., YI, A.K., SHORT, D., and DAVIS, H.L. (1998). Sequence motifs in adenoviral DNA which block immune activation by stimulatory CpG motifs. *Proc. Natl. Acad. Sci. U.S.A.* 95, 12631-12636.
- LEE, E.R., MARSHALL, J., SIEGEL, C.S., JIANG, C., YEW, N.S., NICHOLS, M., NIETUPSKI, J., ZIEGLER, R.J., LANE, M., WANG, K.X., WAN, N.C., SCHEULE, R.K., HARRIS, D.J., SMITH, A.E., and CHENG, S.H. (1996). Detailed analysis of structures and formulations of cationic lipids for efficient gene transfer to the lung. *Hum. Gene Ther.* 7, 1701-1717.
- LI, E., BEARD, C., and JAENISCH, R. (1993). Role for DNA methylation in genomic imprinting. *Nature (London)* 366, 362-365.
- LIPFORD, G.B., BAUER, M., BLANK, C., REITER, R., WAGNER, H., and HEEG, K. (1997). CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: A new class of vaccine adjuvants. *Eur. J. Immunol.* 27, 2340-2344.

- MUIZNIEKS, I., and DOERFLER, W. (1994). The impact of 5'-CG-3' methylation on the activity of different eukaryotic promoters: A comparative study. *FEBS Lett.* **344**, 251-254.
- QIN, L., DING, Y., PAHUD, D.R., CHANG, E., IMPERIALE, M.J., and BROMBERG, J.S. (1997). Promoter attenuation in gene therapy: Interferon- $\gamma$  and tumor necrosis factor- $\alpha$  inhibit transgene expression. *Hum. Gene Ther.* **8**, 2019-2029.
- ROMAN, M., MARTIN-OROZCO, E., GOODMAN, J.S., NGUYEN, M.D., SATO, Y., RONAGHY, A., KORNBLUTH, R.S., RICHMAN, D.D., CARSON, D.A., and RAZ, E. (1997). Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. *Nature Med.* **3**, 849-854.
- SATO, Y., ROMAN, M., TIGHE, H., LEE, D., CORR, M., NGUYEN, M.D., SILVERMAN, G.J., LOTZ, M., CARSON, D.A., and RAZ, E. (1996). Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. *Science* **273**, 352-354.
- SCHEULE, R.K., ST. GEORGE, J.A., BAGLEY, R.G., MARSHALL, J., KAPLAN, J.M., AKITA, G.Y., WANG, K.X., LEE, F.R., HARRIS, D.J., JIANG, C., YEW, N.S., SMITH, A.E., and CHENG, S.H. (1997). Basis of pulmonary toxicity associated with cationic lipid-mediated gene transfer to the mammalian lung. *Hum. Gene Ther.* **8**, 689-707.
- SCHWARTZ, D.A., QUINN, T.J., THORNE, P.S., SAYEED, S., YI, A.K., and KRIEG, A.M. (1997). CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract. *J. Clin. Invest.* **100**, 68-73.
- SPARWASSER, T., MIETHKE, T., LIPFORD, G., ERDMANN, A., HACKER, H., HEEG, K., and WAGNER, H. (1997). Macrophages sense pathogens via DNA motifs: Induction of tumor necrosis factor- $\alpha$ -mediated shock. *Eur. J. Immunol.* **27**, 1671-1679.
- SPARWASSER, T., KOCH, E.S., VABULAS, R.M., HEEG, K., LIPFORD, G.B., ELIWART, J.W., and WAGNER, H. (1998). Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. *Eur. J. Immunol.* **28**, 2045-2054.
- WEINER, G.J., LIU, H.M., WOOLDRIDGE, J.E., DAHLE, C.E., and KRIEG, A.M. (1997). Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. *Proc. Natl. Acad. Sci. U.S.A.* **94**, 10833-10837.
- YANG, Y., LI, Q., ERTL, H.C., and WILSON, J.M. (1995). Cellular and humoral responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. *J. Virol.* **69**, 2004-2015.
- YEW, N.S., WYSOKENSKI, D.M., WANG, K.X., ZIEGLER, R.J., MARSHALL, J., MCNEILLY, D., CHERRY, M., OSBURN, W., and CHENG, S.H. (1997). Optimization of plasmid vectors for high-level expression in lung epithelial cells. *Hum. Gene Ther.* **8**, 575-584.

Address reprint requests to:  
 Dr. Nelson S. Yew  
 Genzyme Corporation  
 31 New York Avenue  
 Framingham, MA 01701-9322

Received for publication August 12, 1998; accepted after revision November 5, 1998.



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>7</sup> : <b>A61K 47/48</b>		<b>A2</b>	(11) International Publication Number: <b>WO 00/45849</b>																														
			(43) International Publication Date: 10 August 2000 (10.08.00)																														
(21) International Application Number: PCT/US00/02943 (22) International Filing Date: 4 February 2000 (04.02.00) (30) Priority Data: 60/118,802 5 February 1999 (05.02.99) US (71) Applicants (for all designated States except US): GENZYME CORPORATION [US/US]; One Mountain Road, Framingham, MA 01701-9322 (US). STRESSGEN BIOTECHNOLOGIES CORPORATION [CA/CA]; 350-4243 Glanford Avenue, Victoria, British Columbia V8Z 4B9 (CA). (72) Inventors; and (73) Inventors/Applicants (for US only): SCHEULE, Ronald, K. [US/US]; 26 East Street, Hopkinton, MA 01748 (US). YEW, Nelson, S. [US/US]; 25 Rockdale Hill Circle, West Upton, MA 01568 (US). MIZZEN, Lee [CA/CA]; 1936 Quimichan Street, Victoria, British Columbia V8S 2C4 (CA). KADHIM, Salam, Abdul [CA/CA]; Unit 66, 14 Erskine Lane, Victoria, British Columbia V8Z 7J7 (CA). (74) Agents: GARRETT, Arthur, S.; Finnegan, Henderson, Farabow, Garrett & Dunner, L.L.P., 1300 I Street N.W., Washington, DC 20005-3315 (US) et al.		(81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  Published Without international search report and to be republished upon receipt of that report.																															
(54) Title: USE OF CATIONIC LIPIDS TO GENERATE ANTI-TUMOR IMMUNITY																																	
(57) Abstract																																	
<p>A method of generating an anti-tumor immune response using a cationic molecule:biologically active molecule complex is provided. In one embodiment, the anti-tumor immune response is a protective, memory-based response. The complex may be administered alone, as the active ingredient in a formulation, or as an adjuvant. The invention also provides for methods of generating an immunostimulatory response against the tumor cell present during treatment by exposing a cationic molecule:biologically active molecule complex to a mammalian cell or a foreign tumor cell.</p>		<table border="1"> <caption>Approximate cytokine levels (pg/ml) from bar charts</caption> <thead> <tr> <th>Cytokine</th> <th>pCF1-CAT</th> <th>(m) pCF1-CAT</th> <th>pCFA-299-CAT</th> <th>pCFA-299-10M-CAT</th> <th>NAIVE</th> </tr> </thead> <tbody> <tr> <td>TNF-α</td> <td>450</td> <td>750</td> <td>600</td> <td>10</td> <td>0</td> </tr> <tr> <td>IFN-γ</td> <td>950</td> <td>450</td> <td>600</td> <td>1100</td> <td>10</td> </tr> <tr> <td>IL-6</td> <td>500</td> <td>200</td> <td>550</td> <td>650</td> <td>10</td> </tr> <tr> <td>IL-12</td> <td>2300</td> <td>800</td> <td>2800</td> <td>2300</td> <td>10</td> </tr> </tbody> </table>		Cytokine	pCF1-CAT	(m) pCF1-CAT	pCFA-299-CAT	pCFA-299-10M-CAT	NAIVE	TNF-α	450	750	600	10	0	IFN-γ	950	450	600	1100	10	IL-6	500	200	550	650	10	IL-12	2300	800	2800	2300	10
Cytokine	pCF1-CAT	(m) pCF1-CAT	pCFA-299-CAT	pCFA-299-10M-CAT	NAIVE																												
TNF-α	450	750	600	10	0																												
IFN-γ	950	450	600	1100	10																												
IL-6	500	200	550	650	10																												
IL-12	2300	800	2800	2300	10																												

*FOR THE PURPOSES OF INFORMATION ONLY*

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## **Use of Cationic Lipids to Generate Anti-Tumor Immunity**

### **Background of the Invention**

The present invention relates to a novel method of suppressing tumor growth and generating protective immunity against tumor recurrence. The present invention also relates to methods and compositions for modulating inflammatory responses in mammals and generating specific immunostimulatory responses.

Lipid mediated gene delivery has become one of the most widely researched areas of gene therapy. Cationic molecules, herein defined as cationic lipids, cationic polymers, and cationic amphiphiles have demonstrated particular promise for efficient intracellular delivery of biologically active molecules. Cationic molecules have polar groups that are capable of being positively charged at or around physiological pH. This property is understood in the art to be important in defining how the molecule interacts with many types of biologically active molecules including, for example, negatively charge polynucleotides such as DNA.

Examples of cationic lipid compounds that are stated to be useful in the intracellular delivery of biologically active molecules can be found throughout the literature along with discussions of properties of cationic lipids that are understood in the art as making them suitable for such applications. The disclosures of several of the examples found in the literature are specifically incorporated by reference herein. (U.S. Patent No. 5,283,185 to Epand et al.; U.S. Patent No. 5,264,618 to Felgner et al.; U.S. Patent No. 5,334,761 to Gebeyehu et al.; and Lee, E.R. et al., Hum. Gene Ther. 7:1701-1717 (1996)).

Another class of cationic lipids with enhanced activity is described, for example, in U.S. Patent No. 5,747,471 to Siegel et al., U.S. Patent No. 5,650,096 to Harris et al., and PCT publication WO 98/02191 published January 22, 1998, the disclosures of which are specifically incorporated by reference herein. These patents also disclose formulations, characteristics and properties of cationic lipids of relevance to the practice of the present invention.

Additionally, several issued U.S. Patents, the disclosures of which are specifically incorporated by reference herein, have described the utility of cationic lipids to deliver polynucleotides to mammalian cells. (U.S. Patent No. 5,676,954 to Brigham et al. and U.S. Patent No. 5,703,055 to Felgner et al.)



However, an inflammatory response associated with lipid gene delivery has been recognized. For example, cationic lipid-mediated gene transfer to the lung induces dose-dependent pulmonary inflammation characterized by an influx of leukocytes (predominantly neutrophils) and elevated levels of inflammatory cytokines such as interleukin-6 (IL-6), tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ), and interferon- $\gamma$  (TNF- $\gamma$ ) in the bronchoalveolar lavage fluid. Histopathological analysis of lung sections treated with the individual components of cationic lipid:DNA complexes suggests that the cationic lipid was a mediator of the observed inflammation.

Additionally, results of clinical studies where CF subjects were subjected to either aerosolized liposomes alone or cationic lipid:DNA complexes indicated that bacterial derived plasmid DNA may also be inflammatory. Each of the cationic lipid:pDNA-treated patients exhibited mild flu-like symptoms (including fever, myalgia, and a reduction in FEV of approximately 15%) over a period of approximately 24 hours. These symptoms were not observed in patients treated with the liposome control. One possible explanation for this response is related to the presence of unmethylated CpG dinucleotide sequences in bacterially-derived pDNA. See Krieg et al., Nature 374: 546-549 (1995); Klinman et al., Proc. Natl. Acad. Sci. USA 83: 2879-2883 (1996); Sato et al., Science 273: 352-354 (1996).

Short regions of genome consisting of unmethylated CpG dinucleotides are known as CpG islands or CpG motifs. Unmethylated CpG dinucleotides are present at a much higher frequency in bacterially-derived plasmid DNA compared to vertebrate DNA and are sometimes characterized as a subtle structural difference between bacterial and vertebrate DNA. For example, compared to DNA of eukaryotic origin, bacterial genomic DNA may contain a 20 fold higher frequency of the dinucleotide sequence CpG. Additionally, unlike eukaryotic DNA where 80% of the cytosines are methylated, those derived from prokaryotic origin are relatively unmethylated. These differences purportedly allow the vertebrate immune system to recognize and respond to DNA of bacterial origin. In this regard, administration of genomic bacterial DNA into an eukaryotic host has been shown to be capable of eliciting a potent immunostimulatory response. See Krieg et al., Trends Microbiol. 4: 73-76 (1995); Ballas et al., J. Immunol. 157: 1840-1845 (1996); Sparwasser et.al., Eur. J. Immunol. 27: 1671-1679 (1997).

Consequently, CpG motifs of bacterial and synthetic dinucleotides have found many uses. The presence of CpG motifs is thought to activate certain immune cells, including B cells, monocytes, dendritic cells, macrophages, and natural killer cells. CpG motifs can also be used to activate protective immune responses against infection, enhance vaccines, activate the immune system against cancer cells, and convert allergic reactions into harmless responses. See Wooldridge et al., Blood 89: 2994-2998 (1997).

Systematic analysis of CpG motifs has indicated that those sequences harboring the CpG motif 5'-RRCGYY-3' were particularly potent at inducing these responses. It was demonstrated that this effect was a consequence of the methylation status of the CpG dinucleotide sequences by experiments showing that administration of either bacterial genomic DNA or synthetic oligonucleotides bearing the RRCGYY sequence that had been pre-methylated with CpG methylase were significantly less immunostimulatory.

Since plasmid DNA used in gene transfer studies is usually isolated from bacterial sources, and because it also harbors bacterial sequences for propagation in the host, it contains a higher frequency of unmethylated CpG sequences. Subsequently, the presence of CpG motifs has been detrimental to the effective introduction of many types of biologically active molecules in gene therapy. For example, the generation of elevated levels of cytokines due to CpG motifs in the BALF has consequences for expression of the therapeutic protein. Several viral promoters, such as the CMV promoter commonly used in gene delivery vectors, are subject to suppression by such cytokines. Furthermore, any additional inflammation or reduction in lung function in patients that already exhibit chronically inflamed, compromised airways represents an increased safety risk.

The presence of CpG motifs on pDNA has also been shown to be capable of stimulating a robust T-helper 1 type response in either transfected monocytes or injected BALB/c mice. Of particular concern for delivery of genes to the lung was the demonstration that bacterial genomic DNA or oligonucleotides containing immunostimulatory CpG motifs are capable of eliciting an acute inflammatory response in airways and in particular caused inflammation in the lower respiratory tract, increasing both cell numbers and elevated levels of the cytokines TNF- $\alpha$ , IL-6 and macrophage inflammatory protein (MIP-2). See Schwartz et al., J. Clin. Invest. 100: 68-73 (1997). Activation of a similar cytokine profile by CpG dinucleotides have also been reported in

murine dendritic cells (Sparwasser et al., Eur. J. Immunol. 28: 2045-2054 (1998)), macrophages (Lipford et al., Eur. J. Immunol. 27: 2340-2344 (1997)), monocytes (Sato et al., Science 273: 352-354 (1995)), and NK cells (Cowdery et al., J. Immunol. 156: 4370-4575 (1996)). A recent study also reported that complexes formed between the cationic lipid DOTMA (N-[1-(2-3--dioleyloxy)propyl]-N,N,N-trimethylammonium chloride) and pDNA enhanced cytokine and cellular levels in the BALF of treated animals. See Friemark et al., J. Immunol. 160: 4580-4586 (1998).

#### Summary of the Invention

The present invention provides for a method of generating an anti-cancer effect in a mammal by administering an effective amount of composition comprising a cationic molecule and a biologically active molecule for the purpose of stimulating an anti-tumor cell response. In a preferred embodiment, the composition comprises a cationic lipid:biologically active molecule complex. In a further preferred embodiment, the biologically active molecule is an immunologically active nucleic acid sequence with or without an expressible cDNA insert.

In a further preferred embodiment, the anti-cancer effect may be an anti-tumor cell response including an apoptotic response, an anti-angiogenic response, or an immune response including an inflammatory response, a humoral response, a cellular response, a Th1-type response, or a Th2-type response.

A subject of the invention is also a method of modulating an immune response in a mammal by administering an effective amount of a composition comprising a cationic molecule and a biologically active molecule, for the purpose of modulating the immune response. The composition may comprise a cationic lipid:biologically active molecule complex and the biologically active molecule may be an immunologically active nucleic acid sequence with or without an expressible cDNA insert. In a preferred embodiment the immune response may be an inflammatory response, a humoral response, a cellular response, a Th1-type response, or a Th2-type response.

Also within the practice of the invention is a method of generating an anti-tumor response in a mammal by contacting a tumor cell with an effective amount of composition comprising a cationic molecule and a biologically active molecule, for the purpose of generating the anti-tumor response. In a preferred embodiment, the anti-tumor response is a

protective anti-tumor immune response that may provide long term protective immune memory. The composition may comprise a cationic lipid:biologically active molecule complex and in a further preferred embodiment the anti-tumor response is a systemic response. Another subject of the invention is the generation of a systemic immune response by administering an effective amount of a composition comprising a cationic lipid and a biologically active molecule to an environment containing a tumor cell in a mammal.

The practice of the invention also provides for a composition effective for generating an immune response against the tumor cell present during treatment. The composition comprises a cationic molecule and a biologically active molecule. Preferably the composition of the invention comprises a cationic lipid:biologically active molecule complex. The invention provides for the delivery of these compositions to a mammal to stimulate an inflammatory response and/or immune response. In a preferred embodiment, the invention provides for a method of stimulating an inflammatory and/or immune response by delivering a composition comprising an immunologically active nucleic acid sequence which may be a bacterial plasmid.

The invention further provides for delivery of a cationic molecule:biologically active molecule complex to a compartment containing a tumor cell, or to a tumor cell itself by any methods known in the art to deliver a biologically active molecule.

In a further embodiment, the invention provides for compositions which are effective for stimulating an inflammatory response or an immune response against the tumor cell present during treatment using a biologically active molecule that comprises an immunologically active nucleic acid sequence, which may or may not contain an expressible cDNA insert. Thus, the methods described above do not require the expression of a transgene.

In another aspect, the invention provides for pharmaceutical compositions comprising a cationic molecule:biologically active molecule complex which stimulates an inflammatory, immune, or anti-tumor response. The compositions may be an active ingredient in a pharmaceutical composition that includes carriers, fillers, extenders, dispersants, creams, gels, solutions and other excipients that are common in the pharmaceutical formulatory arts. The pharmaceutical compositions may be delivered to a

tumor cell or they may be delivered to an environment containing a tumor cell in order to stimulate an immune response against the tumor cell present during treatment.

In a further embodiment, the invention provides for the use of a cationic molecule:biologically active molecule complex as an adjuvant that may be used in combination with another drug or treatment to increase or aid its effect. Examples of drugs or other treatments that may be utilized in combination with a cationic lipid:biologically active molecule complex include but are not limited to known tumor antigens, surgery, cytokines or any treatment that does substantially compromise an immune response.

The invention provides for a method of administering the compositions by any methods that have been employed in the art to effectuate delivery of biologically active molecules to the cells of mammals including but not limited to administration of an aerosolized solution, intravenous injection, or oral, parenteral, intra-peritoneal, intra-nasal, topical, or transmucosal administration.

The invention also provides for a pharmaceutical composition that comprises one or more lipids or other carriers that have been employed in the art to effectuate delivery of biologically active molecules to the cells of mammals, and one or more biologically active molecules, wherein said compositions facilitate intracellular delivery to the cells, tissues or organs of patients of an effective amount of the cationic molecule:biologically active molecule complex. The pharmaceutical compositions of the invention may be formulated to contain one or more additional physiologically acceptable substances including components that: stabilize the compositions for storage; target specific tissues, cells, membranes, or organs in the subject; and/or contribute to the successful delivery of the cationic molecule:biologically active molecule complex.

For pharmaceutical use, a cationic lipid:biologically active molecule complex of the invention may be formulated with one or more additional cationic lipids including those known in the art, or with neutral co-lipids such as dioleoylphosphatidyl-ethanolamine, ("DOPE"), to facilitate delivery to cells the cationic lipid:biologically active molecule complex.

Additional features and advantages of the invention will be set forth in the description which follows, and in part will be apparent from the description, or may be learned by the practice of the invention. The objectives and other advantages of the

invention will be realized and attained by the compounds and methods particularly pointed out in the written description and claims hereof as well as the appended drawings.

#### Brief Description of the Drawings

**Figure 1.** Cytokine analysis of mouse BALF after instillation of GL-67 complexed with methylated or unmethylated pCF1-CAT. Groups of three BALB/c mice were instilled intranasally with 100  $\mu$ l of GL-67:(m)pCF1-CAT, GL-67:pCF1-CAT, GL-67 alone, (m)pCF1-CAT, pCF1-CAT, or vehicle (naive). BALF was collected 24 h after instillation and ELISA assays were used to measure the levels of various cytokines. (m)pCF1-CAT refers to pCF1-CAT that had been methylated by Sss I methylase.

**Figure 2.** Total cell counts (Fig. 2A) and proportion of neutrophils (Fig. 2B) in BALF after administration of cationic lipid:pDNA complexes. Groups of three BALB/c mice were instilled intranasally with 100  $\mu$ l of GL-67:(m)pCF1-CAT, GL-67:pCF1-CAT, GL-67 alone, (m)pCF1-CAT, pCF1-CAT, or vehicle. BALF was collected 24 h post-instillation and total cells and the different cell types were counted. (m)pCF1-CAT refers to pCH-CAT that had been methylated by Sss I methylase while PMN, refers to polymorphonuclear leukocytes.

**Figure 3.** Cytokine analysis of mouse BALF after instillation of GL-67 complexed with mixtures of methylated and unmethylated pCF1-CAT. Sss I-methylated pCF1-CAT was mixed with unmethylated pCF1-CAT at ratios of 0:3, 1:2, 2:1, or 3:0 [(m)pCF1-CAT:pCF1-CAT], then complexed with GL-67 to final concentration of 0.3:1.8 MM (GL-67:pDNA). Groups of three BALB/c mice were instilled intranasally with 100  $\mu$ l of GL-67:pDNA complexes and BALF was collected 24 h after instillation for cytokine assays. Naive animals were treated with vehicle. (m) refers to methylated pCF1-CAT while (un) refers to non-methylated pCF1-CAT.

**Figure 4.** Histopathological analysis of BALB/c mouse lung sections following administration of GL-67 complexed with methylated or unmethylated pCF1-CAT. BALB/c mice were instilled intranasally with 100  $\mu$ l of GL-67:(m)pCF1-CAT, GL-67:pCF1-CAT, GL-67 alone, (m)pCF1-CAT, pCF1-CAT, or vehicle. Mice were sacrificed two days post-instillation and the lungs were processed for histological examination in a blinded manner. Lung inflammation was graded on a scale of 0 to 4, with 0 indicating no change, 1 a minimal change, 2 a mild change, 3 a moderate change, and 4 indicating a severe change

-8-

from a normal lung. (m)pCF1-CAT refers to pCF1-CAT that had been methylated by Sss I methylase.

**Figure 5.** CpG motifs present in pCF1-CAT. The motifs having the sequence 5'-RRCGY-3' are as shown. Numbers in parentheses indicate the nucleotide position of the cytosine residue. The figure uses the following abbreviations: Kan R, the gene for kanamycin; CMV Promoter, cytomegalovirus promoter; CAT, cDNA for chloramphenicol acetyltransferase; BGH PolyA, polyadenylation sequence from bovine growth hormone.

**Figure 6.** Relative levels of CAT expression following methylation or mutagenesis of pCF1-CAT. Groups of three BALB/c mice were instilled intranasally with 100  $\mu$ l of GL-67:pCF1-CAT, GL-67:(m)pCF1-CAT, GL-67:pCFA-299-CAT, or GL-67:pCFA-299-10M-CAT. pCFA-299-CAT harbors a partial deletion of the CMV promoter and pCFA-299-10M-CAT, an additional 10 mutations at CpG sites harboring the sequence motif RRCGY. (m)pCF1-CAT refers to pCF1-CAT that had been methylated by Sss I methylase. Lungs were harvested for CAT analysis at day 2 post-instillation.

**Figure 7.** Cytokine analysis of mouse BALF after instillation of GL-67 complexed with pCF1-CAT and modified forms of pCF1-CAT containing reduced numbers of CpG motifs. Groups of three BALB/c mice were instilled intranasally with 100  $\mu$ l of GL-67:pCF1-CAT, GL-67:(m)pCF1-CAT, GL-67:pCFA-299-CAT, or GL-67:pCFA-299-10M-CAT. BALF was collected 24 h after instillation and ELISA assays for TNF- $\alpha$ , IFN- $\gamma$ , IL-6, and IL-12 were performed. (m)pCF1-CAT refers to pCF1-CAT that had been methylated by Sss I methylase. pCFA-299-CAT harbors a partial deletion of the CMV promoter and pCFA-299-10M-CAT, an additional 10 mutations at CpG sites harboring the sequence motif RRCGY.

#### Detailed Description of the Invention

In the present invention, a cationic molecule:biologically active molecule complex is used to generate an anti-cancer or anti-tumor effect and in a preferred embodiment the anti-tumor effect is generated by stimulating or modulating an immune or inflammatory response in a mammal. The complex may be administered alone, as the active ingredient in a formulation, as an adjuvant, or as part of a composition with another carrier such as a lipid, including cationic lipids, viral vectors, including adenoviruses, and other methods that have

been employed in the art to effectuate delivery of biologically active molecules to the cells of mammals.

In one subject of the invention, the methods of stimulating and/or modulating an immune response by delivering a cationic molecule:biologically active molecule complex to a cell is for the purpose of generating a systemic immune response. The invention provides for the delivery of any cationic molecule:biologically active molecule complex to a mammalian cell to stimulate an inflammatory response and/or an immune response. The invention also provides for methods of generating an immunostimulatory response against a tumor present at the time of treatment by exposing a cationic molecule:biologically active molecule complex to a mammalian cell or a foreign tumor cell.

The immune response stimulated by the cationic molecule:biologically active molecule complex may be an apoptotic response, anti-angiogenic response, inflammatory response, humoral response, cellular response, Th1 or Th2 type response, any other immune response sub-classified as an inflammatory response, or any other immunostimulatory response or anti-cancer response known in the art. Additionally, any other immune response known to be generated by CpG motifs, or bacterially or synthetically derived plasmids, is within the practice of the invention. In a preferred embodiment, the immune response is a protective immune response that may provide long term protective immune memory.

The method of the invention preferably comprises a cationic lipid:biologically active molecule complex. While an inflammatory and/or immune response has been observed following the individual administration of both a cationic lipid and an immunologically active nucleic acid sequence, the preferred response of the invention is obtained by the administration of a composition comprising both a cationic lipid and a biologically active molecule.

The invention provides for the use of any cationic lipid compounds. The traditional use of cationic lipids as carriers of biologically active molecules is to facilitate transfection of the biologically active molecule into a cell. Gene therapy requires successful transfection of target cells in a host. Transfection, which is practically useful per se, may generally be defined as a process of introducing an expressible polynucleotide (for example, a gene, a cDNA, or an mRNA) or other biologically active molecule into a cell. Successful expression of the encoding polynucleotide thus transfected leads to production in the cells of




-10-


a protein. The present invention does not require the transfection of the biologically active molecule or the expression of a transgene. While transfection or expression may be helpful and desired in some situations, stimulation and/or modulation of the inflammatory response or generation of an immune or anti-cancer response may only require delivery of the cationic lipid:biologically active molecule complex to a cell.

Cationic molecules have polar groups that are capable of being positively charged at or around physiological pH. This property is understood in the art to be important in defining how the cationic lipids interact with the many types of biologically active molecules including, for example negatively charged polynucleotides such as DNA. In a preferred embodiment, the invention provides for the use of any cationic lipid and compositions containing them that are useful to facilitate the transport of a biologically active molecule to a cell, tissue, organ, the vascular system, or a body cavity. A number of preferred cationic lipids according to the practice of the invention can be found in U.S. Patent Nos. 5,747,471 & 5,650,096 and PCT publication WO 98/02191. In addition to cationic lipid compounds, these patents disclose numerous preferred co-lipids, biologically active molecules, formulations, procedures, routes of administration, and dosages. Representative cationic lipids that are useful in the practice of the invention are:


-11-




GL 202



GL 89



GL 120



GL 67

and other lipids that are known in the art including those described in U.S. Patents No. 5,747,471 & 5,650,096 and PCT publication WO 98/02191.

The biologically active molecule is preferable an immunologically active nucleic acid sequence, which may be a plasmid, with a non-expressible or expressible DNA insert. However, biologically active molecules included in the practice of the invention include any representative biologically active molecule that can be delivered to a cell in order to stimulate an inflammatory and/or immune response using the methods of the invention including: oligonucleotides containing bacterial sequences; polynucleotides such as genomic DNA, cDNA, and mRNA; ribosomal RNA; antisense polynucleotides; ribozymes; null vectors or vectors without an expressible insert; and low molecular weight biologically active molecules such as hormones and antibiotics.

The immunologically active nucleic acid sequence may be bacterially, synthetically, or vertebrate derived. However, for most applications, a bacterially or synthetically derived sequence is preferred and more preferably a sequence that contains CpG motifs or more even preferably a high frequency of CpG motifs. CpG motifs of bacterial and synthetic origin which are thought to activate certain immune cells including B cells, monocytes, dendritic cells, macrophages, and natural killer cells are within the practice of the invention. Additionally, CpG motifs which can be used to activate protective immune responses against infection, enhance vaccines, and activate the immune system against cancer cells are within the scope of the invention.

In another subject of the invention, a biologically active molecule with CpG motifs stimulates an immune response or an anti-tumor response against a tumor present at the time of treatment when the cationic molecule:biologically active molecule complex is delivered to a host cell. The invention also provides for a method of stimulating an inflammatory and/or immune response by delivering a immunologically active nucleic acid sequence with CpG motifs using a cationic lipid.

Within the practice the invention, an anti-tumor effect may be generated by exposing a tumor cell to a cationic lipid:biologically active molecule complex. The anti-tumor cell response may preferably be a Th1-type response, a Th2-type response, an inflammatory response, an anti-angiogenic response, a pro-apoptotic response, or any other anti-cancer response known in the art. In a preferred embodiment, a cationic lipid:biologically active molecule complex stimulates a long term adaptive immune response against a tumor cell.

The invention also provides for direct administration of the cationic molecule:biologically active molecule complex to a tumor cell in order to generate an a long term adaptive immunostimulatory response and which suppresses or inhibits growth of the tumor cell including administration into the intra-peritoneal, pleural cavity, blood compartment or any other body compartment. Administration may be by injection, intravenously, instillation, inhalation or any other method of administration deemed appropriate by one of sufficient skill in the art including a systemic administration through the vasculature.

Another subject of the invention provides for methods of stimulating an immune response in a mammal by targeting the tumor cell by incorporating targeting agents or using

a cationic molecule which targets the cells, tissues, organs, or vasculature in the area of the tumor cell.

The immune response or anti-tumor effect generated by the methods of the invention may be a localized effect, or in a preferred embodiment, the specific immune response may be a systemic response. More preferably, the specific localized or systemic immune response that is generated may be determined by the type of tumor cell that is exposed to the cationic molecule:biologically active molecule complex and/or the type biologically active molecule or cationic molecule exposed to the tumor cell.

Within the practice of the invention, the biologically active molecule may be immunologically active nucleic acid sequence that may or may not contain an expressible cDNA insert. The methods of invention therefore do not require the expression of a transgene. The subject of the invention also includes the use of an expressible biologically active molecule in the composition or administered as part of a composition in order to generate an immune, inflammatory, or therapeutic response. In the practice of the invention, the methods and compositions of the invention may provide additional therapeutic benefits through the transfection and expression of a biologically active molecule.

Also within the practice of the invention is the administration of compositions comprising a cationic molecule:biologically active molecule complex for the purpose of modulating an inflammatory response. The modulation may be in response to the delivery of the cationic molecule:biologically active molecule complex or the expression of the biologically active molecule and/or the modulation may be regulated by the complex or a transfected biologically active molecule, for example, by using a segment of a plasmid.

#### Other Lipids, including Co-lipids

It has been determined that the stability, delivery and transfection-enhancing capability of cationic molecule compositions can be substantially improved by adding to such formulations small additional amounts of one or more derivatized polyethylene glycol compounds. Such enhanced performance is particularly apparent when measured by stability of cationic lipid formulations to storage and manipulation, including in liquid (suspended) form, and when measured by stability during aerosol delivery of such formulations containing a biologically active molecule, particularly polynucleotides.

According to the practice of the invention, any derivative of polyethylene glycol may be part of a cationic molecule formulation. Complexes have been prepared using a variety of PEG derivatives and all of the PEG derivatives, at a certain minimum cationic lipid:PEG derivative ratio have been able to form stable homogeneous complexes. Although the inventors are not limited as to theory, PEG derivatives can stabilize cationic lipid formulations and enhance the delivery and transfecting properties and the affinity of formulations to biologically active molecules. The use of PEG and PEG derivatives enables one to use a higher ratio of biologically active molecules, especially DNA, to lipid. The following references, specifically incorporated by reference herein, contain more information regarding use of PEG derivatives: Simon J. Eastman et al., Human Gene Therapy 8: 765-773 (1997); and Simon J. Eastman et al. Human Gene Therapy 8: 313-322 (1997). Derivatives of polyethylene glycol useful in the practice of the invention include any PEG polymer derivative with a hydrophobic group attached to the PEG polymer.

For pharmaceutical use, the cationic molecule:biologically molecule complexes of the invention may be formulated with one or more additional cationic lipids including those known in the art, or with neutral co-lipids such as dioleoylphosphatidyl-ethanolamine ("DOPE"), to facilitate delivery of the complexes to cells of a host. The use of neutral co-lipids is optional. Depending on the formulation, including neutral co-lipids may substantially enhance delivery and/or transfection capabilities. Representative neutral co-lipids include dioleoylphosphatidylethanolamine ("DOPE"), diphytanoylphosphatidylethanolamine, lyso-phosphatidylethanolamines, other phosphatidyl-ethanolamines, phosphatidylcholines, lyso-phosphatidylcholines, and cholesterol. Use of diphytanoylphosphatidylethanolamine is highly preferred according to the practice of the present invention, as is use of "DOPE".

#### Other Carriers & Delivery Vehicles

The invention also provides for a composition that comprises one or more lipids or other carriers that have been employed in the art to effectuate delivery of biologically active molecules to the cells of mammals, and one or more biologically active molecule, wherein said compositions facilitate delivery of effective amounts of the biologically active molecules or lipid complexes. Numerous methods and delivery vehicles are within the practice of the invention including viral vectors; DNA encapsulated in liposomes, lipid

delivery vehicles, and naked DNA have been employed to effectuate the delivery of DNA to the cells of mammals. To date, delivery of DNA *in vitro*, *ex vivo*, and *in vivo* has been demonstrated using many of the aforementioned methods.

Other carriers or delivery vehicles that may be included in the compositions of the present invention include viral vectors, adenoviruses, retroviruses, and also non-viral and non-proteinaceous vectors or other alternative approaches that are known in the art to facilitate delivery of biologically active molecules. The person skilled in the art will, of course, take care to choose additional carriers or delivery vehicles and/or their concentration in such a way that the desired properties or activity of the invention are not, or are not substantially, impaired by the envisaged addition.

#### Preparation of Compositions and Administration Thereof

The pharmaceutical compositions of the invention may be formulated to contain one or more additional physiologically acceptable substances that stabilize the compositions for storage, target specific tissues, cells, membranes or organs and/or contribute to the successful intracellular delivery of the cationic lipid:biologically active molecule complex.

The present invention provides for pharmaceutical compositions that facilitate delivery of therapeutically effective amounts of cationic molecule:biologically active molecule complexes. A pharmaceutical composition may comprise a cationic molecule:biologically active molecule complex, lipid or non-lipid carriers, other biologically active molecules, or any other known additives which facilitate delivery of a cationic molecule:biologically active molecule complex.

Pharmaceutical compositions of the invention may facilitate delivery of a cationic molecule:biologically active molecule complexes to numerous cells, tissues and organs such as the gastric mucosa, heart, lung, and solid tumors; cavities and body compartments such as the peritoneal cavity, pleural cavity, blood compartment; and the vascular system and blood cells. Additionally, compositions of the invention facilitate delivery of cationic molecule:biologically active molecule complexes to cells that are maintained *in vitro*, such as in tissue culture.

Cationic lipid species, PEG derivatives, co-lipids and other carriers and delivery vehicles of the invention may be blended so that two or more species of cationic lipid or PEG derivative, co-lipid or carrier are used, in combination, to facilitate delivery of a

-16-

cationic lipid:biologically active molecule complex into target cells and/or into subcellular compartments thereof. Cationic lipids of the invention can also be blended for such use with lipids that are known in the art. Additionally, a targeting agent may be coupled to any combination of cationic lipid, PEG derivative, and co-lipid or other lipid or non-lipid formulation that effectuates delivery of a cationic lipid:biologically active molecule complex to a mammalian cell.

The cationic molecule:biologically active molecule complexes may also be used as an adjuvant that can be combined with another drug or treatment to increase or aid its efficacy. For example, a cationic molecule:biologically active molecule complex may be administered with a known tumor antigen including but not limited to proteins, peptides or cDNA. The cationic molecule:biologically active molecule complexes may also be administered with a tumor cell, or tumor cell lysate, etc, that would contain all tumor antigens. This could be either an autologous (from the patient being treated) tumor cell or an allogeneic (from the same tumor type) tumor cell.

Dosages of the pharmaceutical compositions of the invention will vary, depending on factors such as half-life of the biologically-active molecule and the a cationic molecule:biologically active molecule complex, potency of the biologically-active molecule and the a cationic molecule:biologically active molecule complex, half-life of other delivery vehicles, any potential adverse effects of the cationic molecule:biologically active molecule complex or delivery vehicle if present or of degradation products thereof, the route of administration, the condition of the patient, and the like. Such factors are capable of determination by those skilled in the art.

A variety of methods of administration may be used to provide highly accurate dosages of the compositions of the invention. Such preparations can be administered intravenously, orally, parenterally, topically, transmucosally, or by injection of a preparation into a body cavity of the patient, or by using a sustained-release formulation containing a biodegradable material, or by onsite delivery using additional micelles, gels and liposomes. Nebulizing devices, powder inhalers, dry powder formulations, aerosolized solutions, or other representative of methods that may be used to administer such preparations. The invention provides for a method of administering the complexes by any methods that have

been employed in the art to effectuate delivery of biologically active molecules to the cells of mammals.

Additionally, the compositions, which include therapeutic and pharmaceutically acceptable compositions of the invention, can in general be formulated with excipients (such as the carbohydrates lactose, trehalose, sucrose, mannitol, maltose or galactose, and inorganic or organic salts) and may also be lyophilized (and then rehydrated) in the presence of such excipients prior to use. The complexes may be an active ingredient in a pharmaceutical composition that includes carriers, fillers, extenders, dispersants, creams, gels, solutions and other excipients that are common in the pharmaceutical formulatory arts.

Conditions of optimized formulation for each complex of the invention are capable of determination by those skilled in the pharmaceutical art. Selection of optimum concentrations of particular excipients for particular formulations is subject to experimentation, but can be determined by those skilled in the art for each such formulation.



The invention will be further clarified by the following examples, which are intended to be illustrative of the invention, but not limiting thereof.

### **Examples**

The following Examples are representative of the practice of the invention.

#### **Example 1** *Construction and purification of plasmid DNA.*

The construction and characterization of the plasmid vector pCF1-CAT encoding the reporter gene product chloramphenicol acetyltransferase (CAT) has been described previously. See Yew et al. Hum. Gene Ther. 8: 575-584 (1997). pCF1-CAT contains the strong promoter from the human cytomegalovirus immediate-early gene (CMV), an intron, the bovine growth hormone polyadenylation signal sequence, a pUC origin, and the aminoglycoside 3'-phosphotransferase gene that confers resistance to kanamycin. pCF1-null is analogous to pCF1-CAT except that the cDNA for CAT was deleted. pCFA-299-CAT was constructed by digesting pCFA-CAT (identical to pCF1-CAT except for the addition of a small polylinker 5' of CMV) with Pme I (in the polylinker) and Bgl I (in CMV), blunting the ends with the Klenow fragment of DNA polymerase 1, then replicating. This results in deletion of nucleotides -522 to -300 of the CMV promoter.

Site-directed mutagenesis was performed using the QuickChange Site-Directed Mutagenesis kit (Stratagene) following the protocol described by the manufacturer. One modification was that multiple sets of oligonucleotides were used simultaneously, allowing mutagenesis of three or more sites in a single reaction. The mutations were confirmed by extensive DNA sequencing and restriction enzyme mapping to check for plasmid integrity. pCFA-299-10M-CAT is deleted of the CpG motifs at nucleotides 88, 118, 141, and 224 (number refers to the C residue within the CpG dinucleotide except where indicated and is based on the pCF1-CAT sequence; see Figure 5), and contains 10 point mutations at nucleotides 410, 564, 1497 (G to A), 1887, 2419, 2600, 2696, 3473, 4394 (G to A), and 4551.

Plasmid DNA was prepared by bacterial fermentation and purified by ultrafiltration and sequential column chromatography essentially as described previously. See Lee et al., Hum. Gene Ther. 7: 1701-1717 (1996); Scheule et al., Hum. Gene Ther. 8: 689-707 (1997). The purified preparations contained less than 5 endotoxin units/mg of pDNA as determined by a chromogenic LAL assay (BioWhittaker), less than 10 µg protein/mg pDNA as

determined by the micro BCA assay (Pierce), and less than 10 µg of bacterial chromosomal DNA/mg of pDNA as determined by a dot-blot assay. They were also essentially free of detectable RNA and exhibited spectrophotometric  $A_{260/280}$  ratios of between 1.8 and 2.0.

**Example 2** *In vitro* methylation of pDNA.

Plasmid DNAs were methylated *in vitro* in a 5 ml reaction containing 1 x NEB buffer 2 [50 mM NaCl, 10 mM Tris-HCl, pH 7.9, 10 mM MgCl<sub>2</sub>, 1 mM dithiothreitol], 160 µM S-adenosylmethionine (SAM), 1-3 mg of pDNA, and 1 U of Sss I methylase (New England Biolabs) per µg of pDNA. The mixture was incubated at 37°C for 18 h. Additional SAM was added to a concentration of 150 µM after 4 h of incubation. Mock treatment of pDNA used the same procedure except the Sss I methylase was omitted. Methylated and mock-treated pDNA was centrifuged through a Millipore Probond column, ethanol precipitated, and washed with 70% (v/v) ethanol. The pDNA was resuspended in water to a final concentration of approximately 3 mg/ml. In experiments to examine the effects of Sss I-mediated methylation of pDNA, mock-methylated pDNA was always used as a control.

The extent of pDNA methylation was assessed by digesting 0.2-0.5 µg of the treated pDNA with 10 U BstU I or Hpa II for 1 h, then analyzing the pDNA by agarose gel electrophoresis. Methylated pDNA was protected from BstU I and Hpa II digestion whereas unmethylated or partially methylated pDNA was cleaved. Gel analysis showed that the methylated pDNA was completely protected from either BstU I or Hpa II digestion.

The plasmids used in these studies were highly purified and contained predominantly the supercoiled form, less than 1 endotoxin unit/mg of plasmid and were free of infectious contaminants as determined using a bioburden assay. To assess the role of methylation of CpG dinucleotides in the plasmid DNA on lung inflammation, the purified pDNAs were either methylated or mock methylated *in vitro* using *E. coli* Sss I methylase. This enzyme methylates the cytosine residue (C5) within all CG dinucleotides. The extent of methylation was assessed by monitoring the susceptibility of the modified plasmids to digestion by BstU I or Hpa II but not Msp I. An Sss I-methylated but not the mock-methylated plasmids were completely protected from digestion with BstU I and Hpa II. Methylation of pCF1-CAT also resulted in an approximately 5 fold reduction in expression levels following intranasal administration into lungs of BALB/c mice (Figure 6).

Cytokine levels in the mouse BALF were quantitated using enzyme-linked immunosorbent assay (ELISA) kits as specified by the manufacturers. IFN- $\gamma$ , TNF- $\alpha$ , IL1- $\alpha$ , IL-1 $\beta$ , IL-10 and IL-6 ELISA kits were from Genzyme Corporation, while mKC, MIP-2 and GM-CSF ELISA kits were from R&D Systems, and the Leukotriene B4 ELISA kit was from Perseptive Diagnostics.

The procedures for processing the lung tissues and assay of CAT enzymatic activity have been described elsewhere. See Lee et al., Hum. Gene Ther. 7: 1701-1717 (1996); Yew et al., Hum. Gene Ther. 8: 575-84 (1997).

**Example 3** *Nasal instillation of cationic lipid:pDNA complexes into mice.*

The cationic lipid:pDNA complexes were formed by mixing equal volumes of GL-67:DOPE (1:2) with pDNA as described previously (Lee et al., Hum. Gene Ther. 7: 1701-1717, (1996)) to a final concentration of 0.6:1.2:3.6 mM (GL-67:DOPE:pDNA) or 0.3:0.6:1.8 mM, as indicated in the figure legends. The DNA concentration is expressed in terms of nucleotides, using an average nucleotide molecular weight of 330 daltons. BALB/c mice were instilled intranasally with 100  $\mu$ l of complex as described. See Scheule et al., Hum. Gene Ther. 8: 689-707 (1997). The animals were euthanized and their lungs were lavaged 24 h post-instillation using phosphate-buffered saline (PBS). The recovered BALF were centrifuged at 1,500 rpm for 4 min, and the resulting supernatants were removed and frozen at -80°C for subsequent cytokine analysis. The cell pellets were resuspended in PBS for microscopic determination of cell number and cell types.

**Example 4** *Composition of bronchoalveolar lavage fluid after administration of cationic lipid:pDNA complexes harboring either methylated or unmethylated pDNA.*

The Sss I-methylated (m)pDNA or unmethylated pDNA were complexed with the cationic lipid GL-67 and then instilled intranasally into BALB/c mice. Separate groups of mice were instilled with either (m)pDNA or unmethylated pDNA alone, or vehicle, and their bronchoalveolar lavage fluids collected for analysis at 24 h post-treatment.

To determine whether methylation of pDNA affected the inflammatory response in the lungs, we measured the levels of several different cytokines in the BALF 24 h after instillation. Significantly higher levels of TNF- $\alpha$ , IFN- $\gamma$ , and to a lesser extent IL-6, were found in the BALF of mice that received GL-67:pCF1-CAT when compared to those administered GL-67:(m)pCF1-CAT (Figure 1). Levels of murine KC were also elevated

following instillation of the cationic lipid:pDNA complexes but there was no significant difference in the levels of the cytokine induced by either methylated or unmethylated pDNA complexed with GL-67. In contrast, low levels of these four cytokine were present after instillation with GL-67 alone, (m)pCF1-CAT alone or unmethylated pCF1-CAT alone (Figure 1). However, although the levels of TNF- $\alpha$ , IFN- $\gamma$  and IL-6 were low in the BALF of animals treated with free pDNA compared to complexed pDNA, the levels of these cytokines were invariably higher in the group that received free unmethylated pDNA alone than in the group administered (m)pCF1-CAT. The cytokines IL-10, leukotriene B-4, IL-1 $\beta$ , IL-1 $\alpha$ , MIP-2, and GM-CSF were also assayed but in each case the levels were low and indistinguishable from those attained in naive animals. These results indicated that unmethylated pDNA was inflammatory in the lung and that this response was exacerbated when the pDNA was present in a complex with GL-67. Furthermore, of the cytokines induced by administration of GL-67:pCF1-CAT complexes to the lung, TNF- $\alpha$ , IFN- $\gamma$  and a proportion of the IL-6 were primarily due to the presence of unmethylated pDNA. The cationic lipid GL-67 did not contribute significantly to the cytokine induction in the BALF with the exception of KC where it appeared to work in concert with pDNA to increase its level.

The character of the inflammatory response induced by GL-67:pCF1-CAT was also evaluated by measuring the total number of cells and the differential counts recovered in the BALF of the treated animals. Elevated numbers of polymorphonuclear (PMN) leukocytes were present in the BALF of mice that were instilled with GL-67:pDNA compared to mice that received either GL-67 alone or pDNA alone (Figure 2A). The methylation status of the pDNA in the GL-67:pDNA complex did not significantly affect the overall cell number. However, animals administered (m)pCF1-CAT alone (4 separate experiments) consistently showed a slight reduction in the total number of PMN leukocytes in comparison to those that received pCF1-CAT. An analysis of the different cell types showed an increased proportion of neutrophils in mice that received GL-67:pCF1-CAT compared to mice that received GL-67:(m)pCF1-CAT (Figure 2B). This increase was also observed after instillation of pCF1-CAT alone compared to (m)pCF1-CAT alone. Together, these data indicate that the induction in cellular influx was mediated by both the cationic lipid and pDNA. However, administration of unmethylated pDNA rather than methylated pDNA into

the lung can result in an increase in the number of PMN leukocytes, particularly neutrophils, in the BALF.

Since pCF1-CAT expresses high levels of the CAT reporter enzyme, which is a bacterial protein, there was the possibility that the cytokine response was due to the expression of the foreign protein. Therefore, experiments were repeated using a plasmid vector that contained the same plasmid backbone but lacked any transgene (pCF1-null). The cytokine induction profile after administration of methylated or unmethylated pCF1-null complexed with GL-67 was essentially identical to that attained with pCF1-CAT. This confirmed that the plasmid DNA itself, and not expression of the bacterial CAT, was responsible for the observed cytokine induction.

**Example 5** *Dose-dependent relationship between unmethylated pDNA and cytokine levels.*

To determine whether there was a dose-dependent relationship between the amount of unmethylated pDNA administered to the lung and the levels of induced cytokines, (m)pCF1-CAT was mixed with pCF1-CAT at different ratios before complexing with GL-67. The dose of GL-67 and the total amount of nucleotides delivered remained constant. In this experiment MIP-2 and IL-12 were assayed in addition to TNF- $\alpha$ , IFN- $\gamma$ , IL-6, and mKC. As the proportion of unmethylated pCF1-CAT in the complex increased, there was a corresponding increase in the levels of TNF- $\alpha$ , IFN- $\gamma$ , IL-6, and IL-12 (Figure 3). With IFN- $\gamma$ , IL-6 and IL-12, the stimulated increase in cytokine levels was maximal when the ratio of methylated:unmethylated pDNA was 1:2. This dose-dependent relationship supports the proposal that the induction of TNF- $\alpha$ , IFN- $\gamma$ , IL-6, and IL-12 in the BALF were in direct response to the presence of unmethylated pDNA. This trend was not observed for either KC or MIP-2, consistent with the observations above (Figure 3).

**Example 6** *Histopathological changes in the lung after administration of cationic lipid:methylated pDNA complexes.*

The histopathological changes within BALB/c mouse lungs following administration of either cationic lipid alone, pDNA alone, or cationic lipid:pDNA complexes were also examined. BALB/c mice were instilled intranasally with GL-67:(m)pCF1-CAT, GL-67:pCF1-CAT, GL-67 alone, (m)pCF1-CAT, pCF1-CAT, or water (vehicle control). Mice

were sacrificed 2 days post-instillation and the lungs were processed for histological examination in a blinded manner.

*Histopathology.*

Lungs were fixed by inflation at 30 cm of H<sub>2</sub>O pressure with 2% paraformaldehyde and 0.2% glutaraldehyde. Representative samples were taken from each lung lobe, embedded in glycol methacrylate, sectioned and stained with hematoxylin and eosin. Histopathology on the lung was evaluated in a blinded fashion and graded subjectively using a scale of 0 to 4, where a score of 0 indicates no abnormal findings and a score of 4 reflects severe changes with intense infiltrates. See Scheule et al., Hum. Gene Ther. 8: 689-707 (1997).

Multifocal areas of alveolar inflammation were observed in mice that received GL-67:pDNA complexes. The extent of lung inflammation was graded using a scale from 0 to 4, with 0 indicating no abnormalities, 1 indicating a minimal change, 2 a mild change, 3 a moderate change, and 4 representing severe changes from a normal lung (Figure 4). There was no significant difference in the inflammation score of lungs that received GL-67:pDNA compared to lungs that received GL-67:(m)pDNA complex. Lungs that received GL-67 alone were scored slightly lower than lungs that received lipid:pDNA complex, while minimal inflammation was observed in lungs that received either pDNA or (m)pDNA alone. These results indicated that the presence of unmethylated CpG motifs on the pDNA did not grossly affect the histopathological changes observed in the lung after administration of cationic lipid:pDNA complexes. Furthermore, the majority of the histological changes observed upon administration of the complexes was mediated by the cationic lipid component.

**Example 7**    *Effect of mutating immunostimulatory CpG motifs within pCF1-CAT*

Since a subset of the unmethylated CpG dinucleotides present in pCF1-CAT appears responsible for the majority of the cytokine response, then elimination of these particular CpG motifs should reduce the level of induction. There are 17 motifs in pCF1-CAT having the sequence 5'-RRCGY-3', which have been previously shown to be the sequence context in which the CpG motif was found to be most immunostimulatory (Figure 5). Fourteen of these motifs were eliminated by either deletion or site-directed mutagenesis. The four CpG motifs located within the CMV promoter (at nucleotide positions 88, 118, 141 and 224)

were removed by deletion of a 400 bp fragment containing a portion of the upstream enhancer region, to create pCFA-299-CAT (Figure 5). Ten of the thirteen remaining motifs (at positions 410, 564, 1497, 1887, 2419, 2600, 2696, 3473, 4394 and 4551) were modified using site-directed mutagenesis to create pCFA-299-10M-CAT (Figure 5). The cytosine residue in each motif was mutated to a thymidine residue in each case, with the exception of one motif (nucleotide 1497) within the coding sequence for CAT, and one motif (nucleotide 4394) within the kanamycin resistance gene. With these two motifs, in order to preserve the coding sequence for the respective proteins, the guanine residue of the CpG dinucleotide was changed to an adenosine residue.

The plasmids, pCF1-CAT, (m)pCF1-CAT, pCFA-299-CAT, and pCFA-299-10M-CAT were complexed with cationic lipid GL-67 then instilled intranasally into BALB/c mice. Twenty-four hours after instillation, BALF was collected for cytokine analysis and the lungs harvested for CAT assays. Expression from pCFA-299-CAT, containing the truncated CMV promoter, was approximately one-third that of pCF1-CAT (Figure 6). The expression from pCFA-299-10M-CAT was equivalent to pCFA-299-CAT, indicating that the introduction of the 10 point mutations did not affect transgene expression (Figure 6). As before, high levels of TNF- $\alpha$ , IFN- $\gamma$ , IL-6, and IL-12 were present in the BALF of mice that received unmethylated pCF1-CAT (Figure 7). However, equally high levels of these cytokines were also observed with pCFA-299-CAT and pCFA-299-10M-CAT. Therefore, reducing the content of CpG motifs within the plasmid did not reduce its ability to elevate cytokine levels in the lung. This suggests that other immunostimulatory motifs in addition those harboring the consensus 5'-RRCGY-3' are necessary to stimulate the desired inflammatory response.

**Example 8**    *Effect of cationic lipid:biologically active molecule complexes on tumor growth.*

*B16 melanoma subcutaneous model*

B16/F10 cells ( $5 \times 10^4$ ) were implanted subcutaneously in C57/BL6 mice (8/group) and allowed to grow for ~12 days until they were 3-4 mm in any one dimension. Tumors were injected with lipid:pDNA complexes bearing either the purine nucleoside phosphorylase (PNP) gene, which catalyzes the conversion of several non-toxic deoxyadenosine analogs to highly toxic adenine analogs, or the b-gal gene (control) on days 1

and 3. Animals were administered prodrug (Fludara) intraperitoneally on days 2-7. Compared to untreated animals, the growth of tumors on animals treated with complex, regardless of the transgene, were inhibited by ~60%. In other words, inhibition of tumor growth was achieved even with the intratumoral injection of a control transgene

*B16 melanoma lung metastasis model - lung mets*

On day 0,  $1 \times 10^5$  B16/F10 cells were injected intravenously in C57/BL6 mice. On days 5 and 10, mice were treated with an intravenous injection (100  $\mu$ l) of GL67:pCFA-null complexes. On day 14 mice were sacrificed, lungs excised, fixed and placed in Fekete's solution. The number of lung metastases were counted. Untreated animals had  $26 \pm 4$  (mean  $\pm$  SEM) mets, while the group treated with GL67:pCFA-null had  $9.5 \pm 2.5$  mets, indicating significant ( $p=0.017$ ) efficacy of a lipid:pDNA complex in the absence of an expressing transgene in this model.

*B16 melanoma lung metastasis model - survival*

On day 0, B16/F10 cells were injected intravenously in C57/BL6 mice. On days 5, 10, 15 and 18, one group of mice was treated with an intravenous injection of GL67:pCFA-null complexes. All mice were followed for survival. The untreated group had a median survival of  $27 \pm 1.5$  days, while the group treated with GL67:pCFA-null complexes exhibited a median survival of  $34 \pm 1$  days, a statistically significant ( $p=0.0019$ ; Logrank) increase.

*B16 melanoma lung metastasis model - survival*

In a repeat of the above survival experiment, mice were treated intravenously with GL67:pCFA-Null complexes at either 0.5:2 (Low dose) or 2:2 mM (High dose). Treatment resulted in increased median survival for both groups relative to a control, untreated group of animals, which had a median survival of  $26.8 \pm 0.6$  days. The high dose and low dose groups had median survivals of  $31.6 \pm 1.5$  and  $34.4 \pm 1.2$  days, respectively, which were significantly different from control at  $p$  values of  $<0.01$  and  $<0.0001$ , respectively.

*NuTu/Fischer rat ovarian cancer model*

The ovarian epithelial carcinoma cell NuTu19 is syngeneic for the Fischer 344 rat. See Rose, G.S., et al. Am J Obstet Gynecol 175:593-599 (1996). On day 0,  $1 \times 10^6$  tumor cells in 1 ml were inoculated into the peritoneal cavities of F344 rats. On days 3, 6, and 9, groups (10 animals/group) of animals were treated with 2 ml of either saline or



GL67:pCF1bgal (at a 0.5:2 mM molar ratio), a control vector. The group treated with saline had a median survival of ~92 days, while the group treated with complex had a median survival of ~156 days. These data show a significant effect on survival generated by multiple administrations of a control vector.

#### *MOT Model of Ovarian Cancer*

In the mouse ovarian teratoma (MOT) model (Fekete, E. et al., Cancer Res. 12:438-443 (1952)), tumor cells were implanted into the peritoneal cavity of C3He/FeJ mice (10 mice/group). On three occasions, the mice were treated with saline or GL67:pNull complexes (in saline) by instillation into the peritoneal cavity. The pNull vector is a pCFA backbone without an expressible cDNA insert.

As shown below, all the saline-treated animals died; there were no long term survivors. However, when tumor-bearing animals were treated with GL67:pNull complexes, the percentage of long-term survivors ranged from zero to 70%, depending on the cationic lipid:DNA ratio. Importantly, when these long-term survivors were rechallenged with MOT tumor cells, the percentage of animals that rejected this challenge also ranged from 0 to 70%. This result indicates a formulation-dependent generation of a protective, memory-based immune response that was systemic in nature.

Group	Plasmid	Complex			Treatment Days	Tumor Free Survival (%)	Survival After Rechallenge (%)
		lipid (nmol)	DNA (µg)	Ratio (lipid:DNA) mM			
1	saline	-	-	-	1,8,15	0	-
2	pNull	100	16.5	1:0.5	1,8,15	50	20
3	pNull	100	66	1:2	1,8,15	30	67
4	pNull	100	132	1:4	1,8,15	30	0
5	pNull	100	16.5	1:0.5	2,9,16	70	14
6	pNull	100	66	1:2	2,9,16	40	25
7	pNull	100	132	1:4	2,9,16	50	0

#### **Example 9** *Use of cationic lipid:bacterial genomic DNA as a tumor suppressant.*

##### *AB12 Mesothelioma Model*

AB12 is a murine mesothelioma cell line. BALB/c mice were inoculated intraperitoneally with AB12 mesothelioma cells on day 0. At three time points, days 6, 10

and 14, each group of mice were dosed intraperitoneally with one of the following formulations:

Group A: 50  $\mu$ g bacterial genomic DNA (cut into ~ 4kb fragments);

Group B: 100  $\mu$ g bacterial genomic DNA (cut into ~ 4kb fragments);

Group C: 200 $\mu$ g bacterial genomic DNA (cut into ~ 4kb fragments);

Group D: 100  $\mu$ g bacterial genomic DNA (cut into ~ 4kb fragments) complexed with cationic lipid GL 67 at a 1:4 molar ratio (GL67:DNA); and

Group E: saline.

By 20 days post tumor cell inoculation, there were no surviving mice from the control group, Group E. The results did, however, demonstrate a dose-dependent survival advantage of bacterial genomic DNA. Mice from Group B survived up until day 34 while mice from Group C survived until day 47. At day 60, approximately 12% of the mice from Group C were still alive.

Most surprisingly, there was a significant survival enhancement for the mice treated with the bacterial genomic DNA complexed with cationic lipid GL 67. At day 60, post-tumor cell inoculation, 100% of the mice treated with this complex were still alive.

#### *OVCA Rat Model of Ovarian Cancer*

Administration of bacterial genomic DNA complexed with cationic lipid GL 67 also demonstrated efficacy in the OVCA rat model of ovarian cancer. Each group of rats received an intraperitoneal inoculation of tumor cells at day 0. Following the inoculation of tumor cells, each group of rats received an intraperitoneal dose of one of the following formulations at days 6, 10, 14, and 18:

Group A: bacterial genomic DNA (*E. coli* DNA)

Group B: bacterial genomic DNA (*E. coli* DNA) complexed with cationic lipid GL 67 at a GL 67:DNA molar ratio of 1:4.

Group C: saline.

The results demonstrated a significant survival advantage over the control groups for the group of rats treated with GL 67:DNA complex. For example, less than 30% of the rats treated with saline were alive 25 days post-tumor cell inoculation, while approximately 30% of the rats treated with bacterial genomic DNA survived past 26 days. The rats treated with bacterial genomic DNA complexed with a cationic lipid, however, had a survival rate of

greater than 70% 45 days post-tumor cell inoculation. This data demonstrates that the therapeutic effect is not limited to mouse tumor models.

#### *M3 Melanoma Model*

On day 0, mice were inoculated intraperitoneally with M3 melanoma cells. Following the inoculation of M3 tumor cells, the mice were treated on days 6, 11, 14, and 18 with either the GL 67:pNull complex, which is cationic lipid GL 67 complexed to a null vector (a vector without an expressible insert), or were left untreated (control). All untreated control animals died by day 40, while greater than 85% of the animals treated with the GL 67:pNull complex were alive on day 68.

On day 68, the surviving animals were rechallenged subcutaneously with M3 tumor cells. A naive group of animals was also challenged with these same cells in parallel. All the animals in the naive group died by day 105, while approximately 40% of the animals that had been originally treated with the GL 67:pNull complex survived not only the initial intraperitoneal tumor cells but also the secondary subcutaneous challenge. These results indicate generation of a protective, memory-based immune response.

The M3 melanoma model was also used to demonstrate that this surprising efficacy cannot be achieved with the components of the lipid:DNA complex, but only with the intact complex. Following the intraperitoneal inoculation on day 0 of M3 tumor cells, groups of mice were treated on days 5, 10, 14, and 18 with either GL 67:pNull complexes (lipid:pNull), an equivalent amount of GL 67 (lipid alone), an equivalent amount of pNull DNA (pNull vector alone), or were untreated.

While GL 67 alone showed some benefit, with about 35 % of the mice surviving more than 50 days post tumor cell inoculation, none of the mice treated with the pNull DNA alone or the control survived past 48 days. A significant protection, however, resulted from treatment with the GL 67:pNull complexes, where all of the animals survived at least to day 50. These results not only demonstrate efficacy in an intraperitoneal model of melanoma, they also show that this efficacy cannot be achieved with the individual components of the lipid:DNA complex. This significant efficacy is only observed with the intact complex.

It will be apparent to those skilled in the art that various modifications and variations can be made in the compositions and methods of the present invention without departing from the spirit or scope of the invention. Thus, it is intended that the present description

cover the modifications and variations of this invention provided that they come within the scope of the following claims and their equivalents.

We claim:

1. A method of generating an anti-tumor cell immune response in a mammal comprising the step of administering to said mammal a composition comprising a complex, said complex comprising:

a cationic molecule and an immunologically active nucleic acid sequence without an expressible cDNA insert, wherein said composition is administered in an amount effective to stimulate said anti-tumor cell immune response.

2. A method according to claim 1, wherein said immunologically active nucleic acid sequence is a bacterially derived plasmid.

3. A method according to claim 2, wherein said bacterially derived plasmid comprises CpG rich motifs.

4. A method according to claim 1, wherein said step of administering is accomplished by intra-tumoral administration or administration into a body cavity compartment containing a tumor.

5. A method according to claim 1, wherein said step of administering is chosen from aerosolization, intravenous injection, oral, intraperitoneal, intranasal, topical, and transmucosal administration.

6. A method according to claim 1, wherein said anti-tumor cell response is a systemic response.

7. A method of generating a protective anti-tumor cell immune response in a mammal comprising the step of

administering to said mammal a composition comprising a complex, wherein said complex comprises a cationic molecule and an immunologically active nucleic acid sequence, wherein said complex is provided in an amount effective to stimulate said anti-tumor cell immune response, and wherein said administration is for the purpose of stimulating said protective anti-tumor cell immune response.

8. A method according to claim 7, wherein said immunologically active nucleic acid sequence is not capable of transcription or translation of a biologically active peptide in said mammal.

9. A method according to claim 7, wherein said immunologically active nucleic acid sequence is bacterially derived.

10. A method according to claim 7, wherein said immunologically active nucleic acid sequence is a plasmid.

11. A method according to claim 7, wherein said immunologically active nucleic acid sequence comprises genomic bacterial DNA.

12. A method according to claim 7, wherein said immunologically active nucleic acid sequence is a fragment.

13. A method according to claim 7, wherein said immunologically active nucleic acid sequence comprises CpG rich motifs.

14. A method according to claim 7, wherein said step of administering is accomplished by intra-tumoral administration or administration into a body cavity compartment containing a tumor.

15. A method according to claim 7, wherein said step of administering is chosen from aerosolization, intravenous injection, oral, intraperitoneal, intranasal, topical, and transmucosal administration.

16. A method according to claim 7, wherein said protective anti-tumor cell response is a systemic response.

17. A method of increasing the efficacy of a tumor antigen comprising the administration of an adjuvant, wherein said adjuvant comprises


a cationic molecule:immunologically active nucleic acid sequence complex wherein said immunologically active nucleic acid sequence is without an expressible cDNA insert.

18. A composition for generating a protective anti-tumor cell immune response in a mammal comprising:


a cationic molecule; and

a immunologically active nucleic acid sequence without an expressible cDNA insert.

19. A composition according to claim 18 wherein said cationic molecule is:



20. A method of generating an anti-tumor cell immune response in a mammal comprising the step of administering to said mammal a composition comprising:



and an immunologically active nucleic acid sequence without an expressible cDNA insert, in an amount effective to stimulate said anti-tumor cell immune response.




FIG.1






FIG. 2A





FIG. 2B

**FIG. 3**




FIG. 4

5/7




FIG. 5




FIG. 6




FIG. 7

# PATENT COOPERATION TREATY

# PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>6969.32-304</b>	<b>FOR FURTHER ACTION</b>		see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.
International application No. <b>PCT/US 00/ 02943</b>	International filing date (day/month/year) <b>04/02/2000</b>	(Earliest) Priority Date (day/month/year) <b>05/02/1999</b>	
Applicant  <b>GENZYME CORPORATION et al.</b>			

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 4 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

**1. Basis of the report**

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☐ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of Invention is lacking** (see Box II).

4. With regard to the **title**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☒ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

7  
☐ None of the figures.

## INTERNATIONAL SEARCH REPORT

International Application No

US 00/02943

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K47/48 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, EMBASE, CHEM ABS Data, MEDLINE, BIOSIS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 98 10748 A (GREGORIADIS GREGORY ;UNIV LONDON PHARMACY (GB)) 19 March 1998 (1998-03-19) claims 17,27; example 4 ---	1-20
P,X	WO 99 66879 A (NAT JEWISH MED & RES CENTER) 29 December 1999 (1999-12-29) page 3, line 10-20 page 5, line 25-30 page 15, line 10-20 page 43, line 6-16; claims 1,3,6,7,12,13,15,16,23; example 2 ---	1-20
P,X	WO 99 61056 A (LOEB HEALTH RESEARCH INST AT T ;CPG IMMUNOPHARMACEUTICALS INC (US)) 2 December 1999 (1999-12-02) abstract; claims 1,13,96 ---	1-20
-/--		



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

19 September 2000

Date of mailing of the international search report

28/09/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Gonzalez Ramon, N



## INTERNATIONAL SEARCH REPORT

International Application No

US 00/02943

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, Y	WO 99 61592 A (CHEIL JEDANG CORP ;KIM DOO SIK (KR); PARK WAN JE (KR); JUNG SANG B) 2 December 1999 (1999-12-02) abstract; table 1 page 37 -page 38; claim 8 ----	1-20
A	WO 96 02555 A (UNIV IOWA RES FOUND) 1 February 1996 (1996-02-01) abstract; claims 1,8,9,16; example 3 ----	1-20
Y	WO 98 49288 A (HYBRIDON INC) 5 November 1998 (1998-11-05) claims 8,9; example 6 ----	1-20
Y	WO 98 02191 A (GENZYME CORP) 22 January 1998 (1998-01-22) cited in the application page 9; claims 1,6; figure 1 ----	1-20
Y	US 5 747 471 A (HUBBARD SHIRLEY C ET AL) 5 May 1998 (1998-05-05) cited in the application column 2, line 10-15; claim 8; figure 1A ----	1-20
X, P	BRAMSON J.L. ET AL: "Activation of host antitumoral responses by cationic lipid/DNA complexes" CANCER GENE THERAPY, vol. 7, no. 3, 2000, pages 353-359, XP000938273 abstract page 358, column 2 -page 359 ----	1-20
Y	NEUJAHN D. C.: "Immunostimulatory properties of genomic DNA from different bacterial species" IMMUNOBIOLOGY, vol. 200, 1999, pages 106-119, XP000938322 page 113 page 116, paragraph 3; figures 5,6 ----	1-20
Y	KLINMAN D. M.: "Contribution of CpG motifs to the immunogenicity of DNA vaccines" JOURNAL OF IMMUNOLOGY, vol. 158, 1997, pages 3635-3639, XP000946057 abstract page 3635, column 1 page 3638, column 1 ----- -/--	1-20

# INTERNATIONAL SEARCH REPORT

International Application No

US 00/02943

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y, P	<p>MANDERS P. ET AL: "Immunology of DNA vaccines: CpG motifs and antigen presentation"  INFLAMM RES.,  vol. 49, 2000, pages 199-205, XP000938360  page 202 -page 203; figure 3</p>	1-20
Y	<p>KRIEG A. M. ET AL: "The role of CpG dinucleotides in DNA vaccines"  TRENDS IN MICROBIOLOGY,  vol. 6, no. 1, January 1998 (1998-01),  pages 23-27, XP000938362  page 25, column 2</p>	1-20

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

/US 00/02943

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9810748	A	19-03-1998	AU 4215497 A CN 1237102 A EP 0938298 A	02-04-1998 01-12-1999 01-09-1999
WO 9966879	A	29-12-1999	AU 4827299 A	10-01-2000
WO 9961056	A	02-12-1999	AU 4197799 A	13-12-1999
WO 9961592	A	02-12-1999	AU 7788998 A	13-12-1999
WO 9602555	A	01-02-1996	AU 713040 B AU 1912795 A CA 2194761 A EP 0772619 A JP 10506265 T US 6008200 A	18-11-1999 16-02-1996 01-02-1996 14-05-1997 23-06-1998 28-12-1999
WO 9849288	A	05-11-1998	AU 7171298 A EP 0991755 A	24-11-1998 12-04-2000
WO 9802191	A	22-01-1998	US 5939401 A AU 3663797 A CA 2260029 A EP 0954339 A	17-08-1999 09-02-1998 22-01-1998 10-11-1999
US 5747471	A	05-05-1998	US 5650096 A AU 716706 B AU 4516196 A CA 2205968 A EP 0799059 A JP 10510813 T WO 9618372 A US 6071890 A US 5767099 A US 5840710 A US 5719131 A US 5910487 A US 5783565 A US 5948767 A US 5939401 A	22-07-1997 02-03-2000 03-07-1996 20-06-1996 08-10-1997 20-10-1998 20-06-1996 06-06-2000 16-06-1998 24-11-1998 17-02-1998 08-06-1999 21-07-1998 07-09-1999 17-08-1999